



BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email [info.bmjopen@bmj.com](mailto:info.bmjopen@bmj.com)

# BMJ Open

## Prospective comparison of acupuncture with sham acupuncture to determine impact on sedation and analgesia in mechanically ventilated critically ill patients (PASSION study): protocol for a randomized controlled trial

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-059741
Article Type:	Protocol
Date Submitted by the Author:	03-Dec-2021
Complete List of Authors:	Zhang, Yuzhuo; Guangzhou University of Chinese Medicine Yang, Guang; Guangzhou University of Chinese Medicine Wei, Jinyi; Guangzhou University of Chinese Medicine Chen, Fangliang; Guangzhou University of Chinese Medicine Zhang, Min-Zhou; Guangzhou University of Chinese Medicine; Guangdong Provincial Hospital of Chinese Medicine, Department of Critical Care Medicine Mao, Shuai; Guangzhou University of Chinese Medicine; Guangdong Provincial Hospital of Chinese Medicine, Department of Critical Care Medicine
Keywords:	Adult intensive & critical care < ANAESTHETICS, Adult anaesthesia < ANAESTHETICS, Pain management < ANAESTHETICS

SCHOLARONE™  
Manuscripts

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Prospective comparison of acupuncture with sham acupuncture to determine impact on sedation and analgesia in mechanically ventilated critically ill patients (PASSION study): protocol for a randomized controlled trial**

Yuzhuo Zhang, Ph.D. <sup>1\*</sup>

Guang Yang, M.D. <sup>1,2\*</sup>

Jinyi Wei, M.D. <sup>1</sup>

Fangliang Chen, M.D. <sup>1</sup>

Minzhou Zhang, M.D. <sup>1,2,4Δ</sup>

Shuai Mao, M.D. <sup>1,2,4Δ</sup>

<sup>1</sup> *Second Clinical College, Guangzhou University of Chinese Medicine, Guangzhou 510405, China*

<sup>2</sup> *Department of Critical Care Medicine, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou 510120, China*

<sup>3</sup> *Guangdong Provincial Branch of National Clinical Research Centre for Chinese Medicine Cardiology, Guangzhou 510120, China*

\*The first two authors contribute equally to this article.

ΔCorrespondence to:

1  
2  
3  
4 Prof. Shuai MAO

5  
6 Department of Critical Care Medicine,

7  
8 Guangdong Provincial Hospital of Chinese Medicine,

9  
10 Guangzhou 510120, China

11  
12 Phone: 86-20-81887233

13  
14 Fax: 86-20-81867705

15  
16 E-mail: [maoshuai@gzucm.edu.cn](mailto:maoshuai@gzucm.edu.cn)

17  
18 Or Prof. Minzhou Zhang [minzhouzhang@gzucm.edu.cn](mailto:minzhouzhang@gzucm.edu.cn)

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

ABSTRACT

**Introduction** Sedation and analgesia are recommended used in the intensive care unit (ICU) to enhance patient comfort and safety, facilitate mechanical ventilation, and reduce oxygen demands. However, the increasing evidence demonstrates that excessive sedation and analgesia might prolong mechanical ventilation and increase costs and mortality. Acupuncture, known to attenuate pain, anxiety, and agitation symptoms, might reduce the duration of mechanical ventilation and drug accumulation through avoiding excessively deep sedation and analgesia.

**Methods and analysis** Prospective, randomized controlled trial (RCT) of 180 adult medical/surgical ICU patients with mechanical ventilation needing sedation at 3 ICUs between December 2021 and December 2022. Patients would be treated with analgesia and sedation to achieve desired target sedation levels (Richmond Agitation Sedation Score of -2 to 1) from enrolment until extubation. Enrolled patients will be randomly assigned in a ratio of 1:1:1 to receive deep needle insertion with combined manual and alternating-mode electrical stimulation on acupoints (AC group), superficial needle insertion without manual stimulation and electrical stimulation on non-acupoints (SAC group), or no acupuncture intervention (NAC group).

The primary outcome is the duration of mechanical ventilation from randomization until patients were free of mechanical ventilation (including noninvasive) without reinstitution for the following 48 hours. Secondary endpoints included the dose of

administered sedatives and analgesic at comparable sedation levels throughout the study period, ICU length of stay, hospital length of stay.

**Ethics and dissemination** The trial was approved by the ethics committee at Guangdong Provincial Hospital of Chinese Medicine. We will publish the study results.

**Trial Registration numbers: ChiCTR2100052650**

**Keywords:**

acupuncture; sedation; analgesia; critically ill patients; nonpharmacological therapy

**Word Count: 3805**

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Strengths and limitations of this study**

- ◆ Strengths include objective, methods to reduce bias and careful collection of safety data.
- ◆ The result would demonstrate nonpharmacological therapies could be used as adjuncts to sedatives and analgesics for critically ill patients.
- ◆ Limitations are the non-blinded interventions due to the nature of acupuncture.

For peer review only

Enseignement Supérieur (ABES) .  
Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

For peer review only



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

INTRODUCTION

Sedative and analgesic medications are routinely administered to mechanically ventilated critically ill patients to reduce pain, anxiety, and agitation, as well as to allow patients to tolerate invasive procedures in the intensive care unit (ICU).<sup>1</sup> Opiates are most commonly used as analgesics, while benzodiazepines, propofol, or dexmedetomidine are typically used to prevent or reduce anxiety and agitation.<sup>2</sup> However, overuse of these medications is associated with worsened clinical outcomes, such as prolonged time of mechanical ventilation and hospital length of stay, the increased risk of altered mental status, and even mortality.<sup>3</sup> Thus, reducing the unnecessary dosage of sedative and analgesic medications and their side effects while providing desired sedation has always been a key objective when caring for critically ill patients.

As a therapeutic modality with fewer adverse effects, acupuncture has been used in China and other Asian countries for thousands of years to treat various conditions.<sup>4-6</sup> Studies of acupuncture usually focused on its analgesic effect, such as relieving pain and partly reducing opioid-related side effects during or after surgical procedures.<sup>7-11</sup> Particularly, Centers for Medicare & Medicaid Services (CMS) of USA finalizes a decision to cover acupuncture for chronic low back pain for Medicare beneficiaries from January 2020. Moreover, acupuncture has been demonstrated to reduce sedative demands and improve patient experience during diagnostic endoscopic ultrasound.<sup>12</sup> However, there are few, if any, reports on the effect of acupuncture on reducing excessive sedation and analgesia, especially due to shortening duration of mechanical

ventilation and drug accumulation. Furthermore, there is no evidence for an effect of “true” acupuncture over “sham” acupuncture (superficial needle insertion without manual stimulation at “non-points” or electrical stimulation) on clinical outcomes in critically ill patients needing mechanical ventilation.

Therefore, the PASSION study is designed to investigate the efficacy of acupuncture on sedation and analgesia in mechanically ventilated critically ill patients. We are going to test the hypothesis that acupuncture, as adjunctive therapy to sedation and analgesia therapies, could reduce the duration of mechanical ventilation, the dose of administered sedatives and analgesic, and subsequently improve other clinical outcomes for critically ill patients when compared with sham acupuncture or non-acupuncture.

## METHODS

### Study Design Overview

This is a prospective, parallel-group, controlled trial that will recruit 180 patients with a computer-generated allocation sequence and centralized randomization at tertiary and regional ICUs in 3 hospital (Guangdong Provincial Hospital of Chinese Medicine, Charity Hospital of Guangzhou, University Hospital) in South China. Eligible patients will be randomly assigned, in a ratio of 1:1:1, to receive deep needle insertion with combined manual and alternating-mode electrical stimulation on acupoints (AC group, n =60), superficial needle insertion without manual or electrical stimulation on non-acupoints (SAC group, n =60) for 30 min/day, or no acupuncture intervention (NAC group, n =60) .

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Participants will be assessed the duration of mechanical ventilation, as well as the dose of administered sedatives and analgesic at comparable sedation levels, from randomization until patients were free of mechanical ventilation (including noninvasive) without reinstitution for the following 48 hours. They will be also assessed if acupuncture could achieve better clinical outcomes than SAC or NAC treatment. The design of the trial is summarized in Figure 1.

**Ethical Requirements and Registration**

This protocol and statistical analysis plan was approved by the institutional human Clinical Research Ethical Committee at Guangdong Provincial Hospital of Chinese Medicine (Guangzhou, China) in October 2021 with permission number ZF2021-144-01. The PASSION study was registered on Nov 3, 2021 (ClinicalTrials.gov, number ChiCTR2100052650) and will be conducted following the Declaration of Helsinki from December 2021 to December 2022.

Written informed consent will be provided before enrollment voluntarily. Considering that patients will be sedated following ICU admission, complete adherence to patient consent is deemed impossible. The investigational nature and details of the study, together with the possible risks and all the benefits, will be informed to patients or their authorized surrogates. Written informed consent will be subsequently obtained from either of them. Patients for whom surrogate consent was obtained were asked again to provide informed consent once determined to be competent. They can also withdraw from the study at any time they wish. Also, the investigator can decide to withdraw a

subject from the study for urgent medical reasons. The researcher should complete the case report form (CRF) and record the reason for dropping out.

## Patients

Patients from medical and surgical ICU, aging from 18 to 80 years, for expected mechanical ventilation longer than 24 hours, with agitation and/or discomfort after recovering from drugs used to facilitate endotracheal intubation, requiring sedation and agitation by continuous intravenous administration deemed by the ICU physician, are eligible for participation as soon as they or their authorized surrogates are willing to give informed consent (Table 1).

Exclusion criteria include skin lesions near the acupuncture points; coagulopathy (bleeding time >4 min, thrombocytes <50,000/ $\mu$ l), neurological disease (previous stroke, cerebral palsy, etc.) that would confound the diagnosis of delirium, active seizures, severe dementia, relevant psychiatric disorder, hypohepatia with Childs-Pugh class B or C, second- or third-degree atrioventricular block, alcohol or drug abuse, benzodiazepine dependency, a moribund state with the planned withdrawal of life support, family or physician refusal, pregnancy or lactation, currently participated in any other investigational therapeutic or device trial (Table 1).

## ICU standard treatment

As is standard in each ICU of our study, mechanically ventilated critically ill patients will be treated in a single treatment room. They will be taken care of by a trained ICU physician responsible for all treatment decisions, including sedation analgesia

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

management plans made in consultation with the bedside nurses. They will also receive one-to-one nursing care to adjust the treatment based on a patient's response in time. A team of medical officers will review patient care every day.

**Randomization and blinding**

Eligible patients will be stratified by participating sites to avoid patient-level contamination from the systems-level organizational change in sedation practice and, within each ICU, assigned to the AC, SAC, or NAC group in an equal ratio via computer-generated randomization. In detail, an independent study coordinator will log into the central randomization system using a password-protected account and enter inclusion and exclusion criteria to ensure eligibility. After entering a patient's name and identification card number, a randomization sequence will be generated in blocks of varying sizes and stratified by the site under the control of the central computer system. The random sequence will then be concealed in sealed envelopes and sent to an acupuncturist from the assigned patient's site by the study coordinator.

Allocation of participants will be known to the study coordinator and acupuncturists who will not be involved in outcome assessment and be required to sign a confidentiality agreement about patient allocation. All patients will be treated in a single treatment room. In both AC and SAC groups, patients, bedside nurses, and physicians will be blinded to which acupuncture method the patients would receive. The data collectors and the biostatisticians will be masked from the treatment assignment.

**Acupuncture interventions and procedures**

The acupuncture interventions will be developed by a consensus of acupuncture experts according to the Standards for Reporting of Controlled Trials in Acupuncture (STRICTA).<sup>13</sup> Patients will be assigned in a ratio of 1:1:1 to AC group (n=60), SAC group (n=60), NAC group (n=60). Besides, each group shares the same basic Sedation Analgesia Strategy

For patients in the AC group, 8 disposable sterile acupuncture needles (filiform needles made of stainless steel, Beijing Hanyi Medical Instruments, China) with a length of 40 mm and a diameter of 0.30 mm will be inserted into acupuncture points at Baihui (DU20), Yintang (EX-HN3), and bilateral acupoints of Shenmen (HT7), Hegu (LI4), Taichong (LR3) according to the theory of traditional Chinese medicine. The localization of these points is measured with a unit of *cun*, a traditional Chinese unit of length. One *cun* of a person is defined as the width of the thumb himself, whereas four fingers are defined as 3 *cun*. The insertion will be followed by manual stimulation, a lifting and thrusting technique combined with twirling and rotating the needle sheath to produce a sensation of soreness, numbness, distention, or radiating. This sensation is known as “*Deqi*” and is considered to be indicative of effective needling. Then, alternating-mode electrical stimulation will be given with the parameters: bursts alternating at 2 Hz and 100 Hz every 3 s, with 10-15 mA intensity inducing no discomfort and no muscle contraction.

For patients in the SAC group, superficial needle insertion with a depth of 2 mm and no manual stimulation will be performed for 30 min/day. The same sort of needles with the AC group will be placed 1 cm distant lateral the used acupoints that are not known as

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

AC points. The electrical stimulator will likewise be connected but without electrical stimulation.

Patients in the NAC group will receive no acupuncture-related intervention during the trial. But they could receive a free 12-session daily acupuncture treatment after completing the study at their convenience.

Each Site will be required to have 2 licensed acupuncturists with more than 3 years of experience and specialized training in the acupuncture protocols before starting the study. The acupuncturists will be responsible for the whole acupuncture process but are not further involved in this study.

**Basic Sedation Analgesia Strategy**

In this study, diagnosis and therapeutic management of agitation and pain will be prescribed by the physicians responsible for the clinical care of each patient according to recommended guidelines<sup>14</sup>. An interruptive sedation strategy was used by bedside nurses, and sedation levels and pain intensity were assessed with the Richmond Agitation Sedation Scale (RASS)<sup>15 16</sup>, the Behavioral Pain Scale (BPS) ,or the Numeric Rating Scale (NRS) <sup>17 18</sup> every 4 h in objective to adapt sedatives and analgesics to avoid overuse. Authorized nurses will titrate infusions, including benzodiazepines, propofol, and dexmedetomidine for sedatives and opiates for analgesia, instead of bolus dosing to minimize potential adverse effects.

The sedation analgesia strategy is designed to consider pain treatment before increasing sedatives to minimize the risk of oversedation. The pain will be assessed either by the



BPS in patients unable to communicate or by the NRS, a 1-10 numeric rating scale, in those sufficiently oriented and awake to communicate with the medical staff. Efficacy of the study analgesics drug will be defined as the ability to achieve a score  $< 3$  in both of the pain scoring systems above, evaluated by the bedside nurse. Efficacy of the study sedative drug will be defined as the ability to achieve a sedation score between -2 and 1, set by the patient's medical team using the RASS, a highly reliable and well-validated sedation scale for use within patients over time in the ICU.

Each morning, a daily interruption of sedation (DIS) will be performed at the clinical medical team's discretion. Major opioid infusions needed for active pain will be continued. Recommended criteria to interrupt sedation is used: no drug-induced paralysis, no intracranial hypertension, no myocardial ischemia in the previous 24 h, primary disease healing in progress, hemodynamic stability, the partial pressure of arterial oxygen  $\geq 60$  mmHg, the fraction of inspired oxygen  $\leq 50\%$ , and positive end-expiratory pressure  $\leq 8$  cmH<sub>2</sub>O. The interruption of continuous sedation will be coupled with an assessment hourly for wakefulness, defined as the RASS score 1 to 4, and the ability to perform at least 3 of the following requests: eye-opening, tracking, hand squeezing, and toe moving. With the criteria recommended, patients will be able to pass the DIS if they can tolerate it for 4 h and awakening enough. Then, a spontaneous breathing trial (SBT) will immediately be managed.<sup>19</sup> If patients are insufficient for the DIS, sedatives will be restarted at half the previous dose and then titrated to achieve patient comfort. DIS will be performed the next morning again.

## Extubation Test



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Before extubation, patients will be managed with an SBT. During the SBT, without ventilatory support, patients will be allowed to breathe through a ventilatory circuit with 8cm H<sub>2</sub>O PSV, 0 PEEP, and unchanged FiO<sub>2</sub> from the mechanical ventilation period leading up to the SBT.<sup>20</sup> Criteria for a successful SBT were: respiratory rate between 8 and 35 breaths/min, arterial oxygen saturation > 88%, less than 20% change in mean arterial pressure or heart rate, no signs of respiratory distress and acute cardiac arrhythmia, no use of accessory muscles, no abdominal paradox, absence of sweating, agitation or impaired vigilance status. Patients pass the SBT if they complete a 60 min trial with the success criteria, and extubation will be implemented 6 h later. Patients who fail the SBT will be ventilated immediately with the ventilator settings used before the trial, and sedatives will be restarted at half the previous dose and then titrated to achieve patient comfort. The SBT will be managed the next morning again. Extubation will be implemented following standardized criteria, but the decision to extubate remains upon the authority of the attending physician in charge of the patient. Researchers did not participate in decisions to extubate patients.

The clinical research team should make sure that the overall research protocol, especially the criteria for sedation and definition of successful SBT, is strictly followed by the bedside nurse and medical teams in charge of the patients. Related information will be reported on the Clinical Research Form.

**Assessing Delirium**

Delirium will be measured by the bedside nurses according to the Confusion Assessment Method for the ICU (CAM-ICU) until out of ICU or hospital discharge.<sup>21</sup>

Patients will be considered in this state if they have a RASS score  $\geq -3$  and a positive CAM-ICU, defined as positive with the symptoms of feature 1, feature 2, and either feature 3 or feature 4 as follows:

Feature 1: acute onset of mental status change or fluctuation of mental status

Feature 2: inattention

Feature 3: disorganized thinking

Feature 4: altered level of consciousness

### Adverse Event Monitoring

Adverse events will also be defined a priori and prospectively monitored. Adverse events associated with acupuncture include bleeding, hematoma, and local infection.

Adverse events related to sedation and analgesia include inadequate pain and sedation management (either pain score  $> 4$  and RASS  $> 1$  for 2 consecutive hours or pain and agitation assumed present if receiving neuromuscular blockade), clinically significant iatrogenic withdrawal. Adverse events associated with mechanical ventilation include accidental removal of medical devices, extubation failure (reintubation within 24 hours), pressure ulcers, catheter-associated bloodstream infections, ventilator-associated pneumonia. Every day, study personnel will monitor and assess the seriousness of all adverse events and document all details to determine whether or not any of the events would be related to acupuncture interventions or the study procedure. A report of all

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

serious, unexpected, and study-related adverse events will be presented to an independent data and safety monitoring board and the institutional review board within 7 days of occurrence.

**Outcomes and Data Collection**

The primary outcome is the duration of mechanical ventilation, defined as the time from randomization to successful extubation without reinstitution for the following 48 hours. The secondary outcomes will include the dose of administered sedatives and opiate (absolute value as well as indexed value [total drug in mg/kg ÷ total number of hours from the start of infusion to its ultimate discontinuation]) at comparable clinically individualized target sedation goals throughout the study period, the duration of ICU length of stay, and hospital length of stay. Additional outcomes include the prevalence and days of delirium in ICU, mortality in ICU, and within 28 days after randomization. The day of extubation was considered as the day of death for patients who died while still intubated. Censoring for ICU or hospital length analyses occurred at the time of death or study withdrawal. The number of ventilator free days at 28 days is defined as days alive and not using mechanical ventilation between days 1 and 28. For the 28-day mortality analyses, patients were censored at the time of the last contact alive or at 28 days from enrollment, whichever was first.

Baseline demographic data will be collected from the patients' record by the medical team, including the reason for ICU admission, Acute Physiology and Chronic Health Evaluation (APACHE) II scores and diagnostic classification, Sequential Organ Failure

Assessment (SOFA) scores, hematological and blood chemistry data, and clinical data (detailed information of sedative and analgesic medications administered to the patients before randomization, cardiac safety profile including electrocardiograms and serum troponins, and liver function profile including serum bilirubin and glutamate pyruvate transaminase, etc.). Vital signs such as blood pressure, heart rate, heart rhythm, temperature, and oxygen saturations will be recorded and collected by the bedside nurses, as well as scores of RASS, BPS, NRS, and CAM-ICU. Moreover, adverse events data will also be collected from patients' records.

### Patient and public involvement statement

There was no patient or public involvement in the design, conduct, reporting or dissemination plans of this research.

### Statistical Analysis

Statistical power was estimated using the reduction in duration of mechanical ventilation as the primary outcome. According to Carrasco and colleagues, the mean ( $\pm$ standard deviation) time for current sedation was  $54.7 \pm 12.3$  hours.<sup>22</sup> We calculated that a sample size of 48 patients in each group would provide a power of 90% to detect a 15% relative reduction in intubation time at a two-sided significance level of 0.05. With a dropout rate of 20%, the estimated sample size will be 60 patients per group. Thus a total of 180 patients will be enrolled for the study.

The per-protocol set (PPS), including patients who completed the study without having major protocol violations, is used for the evaluation of clinical outcomes. While the full

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

analysis set (FAS), determined according to the intention-to-treat population (ITT) who underwent randomization except for those who are excluded after randomization, is not only used for evaluation of clinical outcomes but also baseline characteristics to measure the balance of the three groups before intervention. Missing data will be replaced according to the principle of multiple imputation. Continuous data will be presented as median and interquartile range, while categorical data as number and proportions. Normal distribution will be checked by the Kolmogorov test. For continuous variables, normal distributed data will be compared using one-way analysis of variance among three groups, and independent Student's t-test between any of the two groups. While the comparison of non-normally distributed parameters among three groups will be applied by ANOVA (Kruska Wallis), and then Mann-Whitney U-test between any of the two groups. Categorical data will be compared by using Fisher's exact test or the chi-square test. Other factors that might affect the efficacy will be considered as co-variants for covariance analysis or Cox proportional hazards regression model.  $P \leq 0.05$  will be considered to indicate statistical significance. All analyses will be done with R statistical software, version 4.0.2.

**DISCUSSION**

This prospective trial is designed to provide evidence on the beneficial effect of acupuncture on reducing the duration of mechanical ventilation, avoiding excessive sedation and analgesia, as well as improving clinical outcomes in sedating mechanically ventilated ICU patients.

General analgesia and sedation are necessary for mechanically ventilated critically ill patients. However, overuse of sedative and analgesic medications may cause varying degrees of side effects, like respiratory drive reduction.<sup>23</sup> These side effects are associated with worsened clinical outcomes, such as a prolonged time of mechanical ventilation and hospital length of stay, an increased risk of delirium, and even mortality.<sup>24 25</sup> With many sophisticated attempts to mitigate this clinical problem, it has thus far been identified that optimizing analgesia and sedation strategy is able to prevent excessive sedation and analgesia and improve the clinical outcome by reducing the duration and dosage of sedative and analgesic medications.<sup>26-28</sup> Thus, it become a key objective to formulate an intensive sedative and analgesic medications strategy when caring for critically ill patients.

The rationale for evaluating the ability of acupuncture on this subject is based on research findings that acupuncture could manage pain relief and facilitate opioid tapering by increasing the  $\mu$ -opioid receptor binding ability and the opioid peptides release.<sup>29 30</sup> According to the meta-analysis of electroacupuncture on pain relief, the dosage of analgesics needed in AC group was lower than that in NAC group [MD=-6.33,95%CI (-7.20,-5.46), Z=14.24,P<0.00001] (Figure 2).<sup>31-35</sup> Meanwhile, acupuncture, without adverse effect, has been shown to exert sedation effects in various medical conditions. As it shown in meta-analysis, the bispectral index (BIS) values in AC group was also lower than that in NAC group [MD=-9.98,95%CI(-10.54,-9.42),Z=34.84,P<0.00001] (Figure 3).<sup>33 36-38</sup> With these promising results, it is

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

meaningful to assess acupuncture as a potential analgesia and sedation strategy in ameliorating the clinical outcomes in mechanically ventilated critically ill patients.

RCT has been recognized as the gold standard for clinical trials since the late 20th century.<sup>39</sup> Another important designed technique to improve the quality of clinical trials is blinding. Over the past several decades, RCT and blinding have been used to avoid bias (selection bias, performance bias, and ascertainment bias) in clinical trials and improve the reliability of effects assessment. Sham acupuncture, aiming to blind the participants and control therapeutic components, is designed as a placebo control. However, this acupuncture technique is relatively difficult to fabricate because it should be both biologically inert and psychologically indistinguishable.<sup>40</sup> Even previous experience of acupuncture feeling might impact the present perception of verum and sham acupuncture intervention.

In PASSION study, we utilize a rigorous set of methods to minimize bias, such as computer-generated central randomization, parallel control design, and statistical analysis according to the intent-to-treat principle. In control design, the superficial needle insertion without manual or electrical stimulation at non-point is applied to simulate deep skin penetration in the SAC group, which is used as the most predominant type of sham electropuncture method to ensure blinding according to the published literature.<sup>41</sup> However, a few studies reported that superficial needle insertion at non-acupoints might not be physiologically inert since the locations of points are nearby true acupoints.<sup>42 43</sup> Moreover, researchers found that even mechanical non-penetration can evoke slight acupressure effects and physiological activity.<sup>44</sup> Both of these factors will



1  
2  
3  
4 affect the effect assessment of acupuncture. Thus, the NA group, avoiding all  
5  
6 therapeutic components, is designed to clarify if the sham acupuncture could be  
7  
8 regarded as physiologically inert, as well as compared with the results of the AC group.  
9

10  
11  
12 A potential limitation of this trial is blinding. Given the nature of acupuncture, the  
13  
14 patients and members of the medical team in the NA group are impossible to be blinded  
15  
16 throughout the entire duration of this trial. However, adequate measures will be taken  
17  
18 to put other people in a masked state. We will formulate a set of isolation and secrecy  
19  
20 strategies for the study coordinator and acupuncturists to achieve satisfactory blinding  
21  
22 levels in treatment administration. Thus, in both AC and SAC groups, patients and their  
23  
24 medical team members will be blinded to the patients' acupuncture method. The data  
25  
26 collectors and the biostatisticians will also be masked of the treatment assignment.  
27  
28  
29

30  
31  
32 The PASSION study is designed to demonstrate the efficacy of acupuncture on sedation  
33  
34 and analgesia in mechanically ventilated critically ill patients. We expect the finding  
35  
36 would provide evidence-based recommendations for acupuncture use for sedation and  
37  
38 analgesia in critically ill patients with mechanical ventilation.  
39  
40  
41  
42  
43  
44  
45  
46  
47

#### 48 **FUNDING STATEMENT:**

49  
50 This study was funded by National Science Foundation (grant No.  
51  
52 81703877&82074216&82004135), Science and Technology Planning Project of  
53  
54 Guangzhou (202102010301), a Featured Innovative Project from Guangdong Provincial  
55  
56 Universities (2019KTSCX029), Young Talents Support Project from China Association  
57  
58  
59  
60



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

of Chinese Medicine (2019-QNRC2-C06), Team of prevention and treatment of acute myocardial infarction with Chinese medicine (2019KCXTD009), Foundation of Guangdong Province of CM (20211187&20201142).

**DISCLAIMER**

The sponsors have had no role in the project development, in the collection of data, in the preparation of this manuscript, nor the decision to publish. The researchers have complete independence from the sources of funding in all aspects of this study.

**PATIENT CONSENT FOR PUBLICATION**

Consent obtained from parent(s)/guardian(s).

**PROVENANCE AND PEER REVIEW**

Not commissioned; externally peer reviewed.

**ETHICS AND DISSEMINATION**

The study was reviewed and approved by Ethics Committee of Guangdong Province Hospital of Chinese Medicine at Guangzhou University of Chinese Medicine (ZF2021-144-01) and performed in accordance with Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (publication No. 85-23, revised 1996).

**COMPETING INTERESTS STATEMENT**

All authors declare that they have no conflict of interest.

**AUTHORS' CONTRIBUTIONS**

YZ & SM drafted this manuscript; GY, JW & FC made statistical analysis; MZZ made a critical revision of the manuscript and contributed to the rationalization of the study.

All authors read and approved the final manuscript.

## REFERENCE

For peer review only

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1. Coursin DB, Skrobik Y. What Is Safe Sedation in the ICU? *New England Journal of Medicine* 2019;380(26):2577-78.  
doi: 10.1056/NEJMe1906522

2. Subramaniam B, Shankar P, Shaefi S, et al. Effect of Intravenous Acetaminophen vs Placebo Combined With Propofol or Dexmedetomidine on Postoperative Delirium Among Older Patients Following Cardiac Surgery The DEXACET Randomized Clinical Trial. *Jama-Journal of the American Medical Association* 2019;321(7):686-96.  
doi: 10.1001/jama.2019.0234

3. Shelton KT, Qu J, Bilotta F, et al. Minimizing ICU Neurological Dysfunction with Dexmedetomidine-induced Sleep (MINDDS): protocol for a randomised, double-blind, parallel-arm, placebo-controlled trial. *BMJ Open* 2018;8(4):e020316. doi: 10.1136/bmjopen-2017-020316 [published Online First: 2018/04/22]

4. Zhao L, Li D, Zheng H, et al. Acupuncture as Adjunctive Therapy for Chronic Stable Angina: A Randomized Clinical Trial. *Jama Internal Medicine* 2019;179(10):1388-97. doi: 10.1001/jamainternmed.2019.2407

5. Garcia MK, Meng Z, Rosenthal DI, et al. Effect of True and Sham Acupuncture on Radiation-Induced Xerostomia Among Patients With Head and Neck Cancer: A Randomized Clinical Trial. *Jama Network Open* 2019;2(12):e1916910. doi: 10.1001/jamanetworkopen.2019.16910

6. Pei W, Peng R, Gu Y, et al. Research trends of acupuncture therapy on insomnia in two decades (from 1999 to 2018): a bibliometric analysis. *Bmc Complementary and Alternative Medicine* 2019;19(1):225. doi: 10.1186/s12906-019-2606-5

7. He Y, Guo X, May BH, et al. Clinical Evidence for Association of Acupuncture and Acupressure With Improved Cancer Pain A Systematic Review and Meta-Analysis. *Jama Oncology* 2020;6(2):271-78. doi: 10.1001/jamaoncol.2019.5233

8. Smith CA, Armour M, Zhu X, et al. Acupuncture for dysmenorrhoea. *Cochrane Database of Systematic Reviews* 2016(4):CD007854. doi: 10.1002/14651858.CD007854.pub3

9. Manheimer E, Cheng K, Wieland LS, et al. Acupuncture for hip osteoarthritis. *Cochrane Database of Systematic Reviews* 2018(5):CD013010. doi: 10.1002/14651858.Cd013010
10. Dingemann J, Plewig B, Baumann I, et al. Acupuncture in posttonsillectomy pain A prospective, double-blinded, randomized, controlled trial. *Hno* 2017;65:73-79. doi: 10.1007/s00106-016-0290-z
11. Wu M-S, Chen K-H, Chen IF, et al. The Efficacy of Acupuncture in Post-Operative Pain Management: A Systematic Review and Meta-Analysis. *Plos One* 2016;11(3):e0150367. doi: 10.1371/journal.pone.0150367
12. Teoh AYB, Chong CCN, Leung WW, et al. Electroacupuncture-reduced sedative and analgesic requirements for diagnostic EUS: a prospective, randomized, double-blinded, sham-controlled study. *Gastrointestinal Endoscopy* 2018;87(2):476-85. doi: 10.1016/j.gie.2017.07.029
13. MacPherson H, Altman DG, Hammerschlag R, et al. Revised STAndards for Reporting Interventions in Clinical Trials of Acupuncture (STRICTA): extending the CONSORT statement. *Acupuncture in Medicine* 2010;28(2):83-93. doi: 10.1136/aim.2009.001370
14. Barr J, Fraser GL, Puntillo K, et al. Clinical Practice Guidelines for the Management of Pain, Agitation, and Delirium in Adult Patients in the Intensive Care Unit. *Critical Care Medicine* 2013;41(1):263-306. doi: 10.1097/CCM.0b013e3182783b72
15. Ely EW, Truman B, Shintani A, et al. Monitoring sedation status over time in ICU patients - Reliability and validity of the Richmond Agitation-Sedation Scale (RASS). *Jama-Journal of the American Medical Association* 2003;289(22):2983-91. doi: 10.1001/jama.289.22.2983
16. Sessler CN, Gosnell MS, Grap MJ, et al. The Richmond Agitation-Sedation Scale - Validity and reliability in adult intensive care unit patients. *American Journal of Respiratory and Critical Care Medicine* 2002;166(10):1338-44. doi: 10.1164/rccm.2107138
17. Payen JF, Bru O, Bosson JL, et al. Assessing pain in critically ill sedated patients by using a behavioral pain scale.

*Critical Care Medicine* 2001;29(12):2258-63. doi: 10.1097/00003246-200112000-00004

18. Chanques G, Viel E, Constantin J-M, et al. The measurement of pain in intensive care unit: Comparison of 5 self-report intensity scales. *Pain* 2010;151(3):711-21. doi: 10.1016/j.pain.2010.08.039

19. Girard TD, Kress JP, Fuchs BD, et al. Efficacy and safety of a paired sedation and ventilator weaning protocol for mechanically ventilated patients in intensive care (Awakening and Breathing Controlled trial): a randomised controlled trial. *Lancet* 2008;371(9607):126-34. doi: 10.1016/s0140-6736(08)60105-1

20. Subira C, Hernandez G, Vazquez A, et al. Effect of Pressure Support vs T-Piece Ventilation Strategies During Spontaneous Breathing Trials on Successful Extubation Among Patients Receiving Mechanical Ventilation A Randomized Clinical Trial. *Jama-Journal of the American Medical Association* 2019;321(22):2175-82. doi: 10.1001/jama.2019.7234

21. Hui D, Frisbee-Hume S, Wilson A, et al. Effect of Lorazepam With Haloperidol vs Haloperidol Alone on Agitated Delirium in Patients With Advanced Cancer Receiving Palliative Care A Randomized Clinical Trial. *Jama-Journal of the American Medical Association* 2017;318(11):1047-56. doi: 10.1001/jama.2017.11468

22. Carrasco G, Molina R, Costa J, et al. Propofol vs midazolam in short-, medium-, and long-term sedation of critically ill patients. A cost-benefit analysis. *Chest* 1993;103(2):557-64. doi: 10.1378/chest.103.2.557

23. Liu L, Wu A-P, Yang Y, et al. Effects of Propofol on Respiratory Drive and Patient-ventilator Synchrony during Pressure Support Ventilation in Postoperative Patients: A Prospective Study. *Chinese Medical Journal* 2017;130(10):1155-60. doi: 10.4103/0366-6999.205864

24. Kollef MH, Levy NT, Ahrens TS, et al. The use of continuous IV sedation is associated with prolongation of mechanical ventilation. *Chest* 1998;114(2):541-48. doi: 10.1378/chest.114.2.541

25. Ouimet S, Kavanagh BP, Gottfried S, et al. Incidence, risk factors and consequences of ICU delirium. *Intensive Care Medicine* 2007;33(1):66-73. doi: 10.1007/s00134-006-0399-8

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies. Enseignement Supérieur (ABES).

26. Chanques G, Conseil M, Roger C, et al. Immediate interruption of sedation compared with usual sedation care in critically ill postoperative patients (SOS-Ventilation): a randomised, parallel-group clinical trial. *Lancet Respiratory Medicine* 2017;5(10):795-805. doi: 10.1016/s2213-2600(17)30304-1
27. Mehta S, Burry L, Cook D, et al. Daily Sedation Interruption in Mechanically Ventilated Critically Ill Patients Cared for With a Sedation Protocol A Randomized Controlled Trial. *Jama-Journal of the American Medical Association* 2012;308(19):1985-92. doi: 10.1001/jama.2012.13872
28. Asmussen S, Przkora R, Maybauer DM, et al. Meta-Analysis of Electroacupuncture in Cardiac Anesthesia and Intensive Care. *Journal of Intensive Care Medicine* 2019;34(8):652-61. doi: 10.1177/0885066617708558
29. Harris RE, Zubieta J-K, Scott DJ, et al. Traditional Chinese acupuncture and placebo (sham) acupuncture are differentiated by their effects on mu-opioid receptors (MORs). *Neuroimage* 2009;47(3):1077-85. doi: 10.1016/j.neuroimage.2009.05.083
30. Han JS. Acupuncture: neuropeptide release produced by electrical stimulation of different frequencies. *Trends in Neurosciences* 2003;26(1):17-22. doi: 10.1016/s0166-2236(02)00006-1
31. Lin JG, Lo MW, Wen YR, et al. The effect of high and low frequency electroacupuncture in pain after lower abdominal surgery. *Pain* 2002;99(3):509-14. doi: 10.1016/S0304-3959(02)00261-0 [published Online First: 2002/10/31]
32. Chiu JH, Chen WS, Chen CH, et al. Effect of transcutaneous electrical nerve stimulation for pain relief on patients undergoing hemorrhoidectomy: prospective, randomized, controlled trial. *Dis Colon Rectum* 1999;42(2):180-5. doi: 10.1007/BF02237124 [published Online First: 1999/04/22]
33. Chen J, Zhang Y, Li X, et al. Efficacy of transcutaneous electrical acupoint stimulation combined with general anesthesia for sedation and postoperative analgesia in minimally invasive lung cancer surgery: A randomized, double-blind, placebo-controlled trial. *Thorac Cancer* 2020;11(4):928-34. doi: 10.1111/1759-7714.13343 [published Online First: 2020/02/18]

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

34. El-Rakshy M, Clark SC, Thompson J, et al. Effect of intraoperative electroacupuncture on postoperative pain, analgesic requirements, nausea and sedation: a randomised controlled trial. *Acupunct Med* 2009;27(1):9-12. doi: 10.1136/aim.2008.000075 [published Online First: 2009/04/17]

35. Chen Y, Gong Y, Huai X, et al. Effects of transcutaneous electrical acupuncture point stimulation on peripheral capillary oxygen saturation in elderly patients undergoing colonoscopy with sedation: a prospective randomized controlled trial. *Acupunct Med* 2021;39(4):292-98. doi: 10.1177/0964528420960479 [published Online First: 2020/12/02]

36. Fleckenstein J, Baeumler P, Gurschler C, et al. Acupuncture reduces the time from extubation to 'ready for discharge' from the post anaesthesia care unit: results from the randomised controlled AcuARP trial. *Sci Rep* 2018;8(1):15734. doi: 10.1038/s41598-018-33459-y [published Online First: 2018/10/26]

37. Cabrini L, Gioia L, Gemma M, et al. Bispectral index evaluation of the sedative effect of acupuncture in healthy volunteers. *J Clin Monit Comput* 2006;20(5):311-5. doi: 10.1007/s10877-006-9026-z [published Online First: 2006/09/22]

38. Zheng X, Meng JB, Fang Q. Electroacupuncture reduces the dose of midazolam monitored by the bispectral index in critically ill patients with mechanical ventilation: an exploratory study. *Acupunct Med* 2012;30(2):78-84. doi: 10.1136/acupmed-2011-010095 [published Online First: 2012/03/31]

39. Meldrum ML. A brief history of the randomized controlled trial - From oranges and lemons to the gold standard. *Hematology-Oncology Clinics of North America* 2000;14(4):745-60. doi: 10.1016/s0889-8588(05)70309-9

40. Boutron I, Guittet L, Estellat C, et al. Reporting methods of blinding in randomized trials assessing nonpharmacological treatments. *Plos Medicine* 2007;4(2):370-80. doi: 10.1371/journal.pmed.0040061

41. Chen Z-x, Li Y, Zhang X-g, et al. Sham Electroacupuncture Methods in Randomized Controlled Trials. *Scientific Reports* 2017;7:40837. doi: 10.1038/srep40837

42. Lund I, Lundeberg T. Are minimal, superficial or sham acupuncture procedures acceptable as inert placebo controls?

*Acupuncture in medicine : journal of the British Medical Acupuncture Society* 2006;24(1):13-5.

43. Lundeberg T, Lund I, Naslund J, et al. The Emperor's sham - wrong assumption that sham needling is sham.

*Acupuncture in Medicine* 2008;26(4):239-42. doi: 10.1136/aim.26.4.239

44. Kim T-H, Lee MS, Alraek T, et al. Acupuncture in sham device controlled trials may not be as effective as acupuncture

in the real world: a preliminary network meta-analysis of studies of acupuncture for hot flashes in menopausal women. *Acupuncture in Medicine* 2020;38(1):37-44. doi: 10.1136/acupmed-2018-011671



**Table 1. Inclusion and exclusion criteria**

A. Inclusion criteria	B. Exclusion criteria
1. Aged 18 years or over and under 80 years;	1. Skin lesions near the acupuncture points;
2. Required mechanical ventilation >24 hours;	2. Coagulopathy (bleeding time >4 min, thrombocytes <50,000/μl;
3. Continuous intravenous administration of sedative and analgesic medications;	3. Hypohepatia with Childs-Pugh class B or C;
4. Willingness to provide informed consent prior to enrollment;	4. Second- or third-degree atrioventricular block;
5. Be able to comply with all follow-up evaluations (in investigator's opinion).	5. Severe dementia;
	6. Psychiatric disorder;
	7. Neurological disease;
	8. Active seizures;
	9. Alcohol or drug abuse;
	10. Benzodiazepine dependency;
	11. Moribund state with the planned withdrawal of life support;
	12. Family or physician refusal;

13. Pregnancy or lactation;

14. Currently participated in any other  
investigational therapeutic or device trial.

For peer review only

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Figure legend:

Figure 1. Trial design of PASSION study

Figure 2. Forest plot of AC group versus NAC group.

Figure 3. Forest plot of AC group versus NAC group.

For peer review only

Enseignement Supérieur (ABES) .  
Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.




Figure 1

130x165mm (300 x 300 DPI)




Figure 2

219x46mm (300 x 300 DPI)




Figure 3

219x45mm (300 x 300 DPI)

# BMJ Open

## Prospective comparison of acupuncture with sham acupuncture to determine impact on sedation and analgesia in mechanically ventilated critically ill patients (PASSION study): protocol for a randomized controlled trial

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-059741.R1
Article Type:	Protocol
Date Submitted by the Author:	14-May-2022
Complete List of Authors:	Zhang, Yuzhuo; Guangzhou University of Chinese Medicine Yang, Guang; Guangzhou University of Chinese Medicine Wei, Jinyi; Guangzhou University of Chinese Medicine Chen, Fangliang; Guangzhou University of Chinese Medicine Zhang, Min-Zhou; Guangzhou University of Chinese Medicine Mao, Shuai; Guangzhou University of Chinese Medicine; Guangdong Provincial Hospital of Chinese Medicine, Department of Critical Care Medicine
<b>Primary Subject Heading</b>:	Intensive care
Secondary Subject Heading:	Complementary medicine
Keywords:	Adult intensive & critical care < ANAESTHETICS, Adult anaesthesia < ANAESTHETICS, Pain management < ANAESTHETICS

SCHOLARONE™  
Manuscripts

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Prospective comparison of acupuncture with sham acupuncture to determine impact on sedation and analgesia in mechanically ventilated critically ill patients (PASSION study): Protocol for a randomized controlled trial**

Yuzhuo Zhang, Ph.D.<sup>1\*</sup>

Guang Yang, M.D.<sup>1,2\*</sup>

Jinyi Wei, M.D.<sup>1</sup>

Fangliang Chen, M.D.<sup>1</sup>

Minzhou Zhang, M.D.<sup>1,2,4Δ</sup>

Shuai Mao, M.D.<sup>1,2,4Δ</sup>

<sup>1</sup> *Second Clinical College, Guangzhou University of Chinese Medicine, Guangzhou 510405, China*

<sup>2</sup> *Department of Critical Care Medicine, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou 510120, China*

<sup>3</sup> *Guangdong Provincial Branch of National Clinical Research Centre for Chinese Medicine Cardiology, Guangzhou 510120, China*

\*The first two authors contribute equally to this article.

ΔCorrespondence to:

Prof. Shuai MAO

Department of Critical Care Medicine,

Guangdong Provincial Hospital of Chinese Medicine,

Guangzhou 510120, China

Phone: 86-20-81887233

Fax: 86-20-81867705

E-mail: [maoshuai@gzucm.edu.cn](mailto:maoshuai@gzucm.edu.cn)

Or Prof. Minzhou Zhang [minzhouzhang@gzucm.edu.cn](mailto:minzhouzhang@gzucm.edu.cn)



## ABSTRACT

**Introduction** Sedation and analgesia are recommended to be employed in the intensive care unit (ICU) to enhance patient comfort and safety, facilitate mechanical ventilation, and reduce oxygen demands. However, the increasing evidence demonstrates that excessive sedation and analgesia might prolong mechanical ventilation and increase costs and mortality. Acupuncture is known to be able to attenuate pain, anxiety, and agitation symptoms while avoiding excessive sedation and analgesia caused by drugs. Therefore, we present a protocol to investigate whether acupuncture, used for sedation and analgesia, can reduce the duration of mechanical ventilation, save medical resources, and reduce the mortality of critically ill patients receiving mechanical ventilation.

**Methods and analysis** Prospective, randomized controlled trial (RCT) is conducted on 180 adult medical/surgical ICU patients with mechanical ventilation needing sedation at 3 ICUs between 03 November 2021 and 16 August 2023. Patients will be treated with analgesia and sedation to achieve desired target sedation levels (Richmond Agitation Sedation Score of -2 to 1). Enrolled patients will be randomly assigned in a ratio of 1:1:1 to receive deep needle insertion with combined manual and alternating-mode electrical stimulation on acupoints (AC group), superficial needle insertion without manual stimulation and electrical stimulation on non-acupoints (SAC group), or no acupuncture intervention (NAC group).

The primary outcome is the duration of mechanical ventilation from randomization until patients are free of mechanical ventilation (including noninvasive) without reinstitution for the following 48 hours. Secondary endpoints include the dose of administered sedatives and analgesic at comparable sedation levels throughout the study, ICU length of stay, hospital length of stay. Additional outcomes include the prevalence and days of delirium in ICU, mortality in ICU and within 28 days after randomization, and the number of ventilator free days in 28 days.

1  
2  
3  
4 54  
5  
6 55  
7  
8  
9 56  
10  
11  
12 57  
13  
14  
15 58  
16  
17 59  
18  
19 60  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Ethics and dissemination** This trial was approved by the ethics committee at Guangdong Provincial Hospital of Chinese Medicine. We will publish the study results.

**Trial Registration numbers: ChiCTR2100052650**

**Keywords:**

acupuncture; sedation; analgesia; critically ill patients; nonpharmacological therapy

**Word Count: 3805**

## Strengths and limitations of this study

- This study is an RCT to investigate both the sedative and analgesic effects of acupuncture on critically ill patients needing mechanical ventilation in ICU.
- This study provides a sedative and analgesic strategy for mechanically ventilated critically ill patients with less side effects.
- The primary endpoint is the duration of mechanical ventilation from randomization until patients are free of mechanical ventilation (including noninvasive) without reinstitution for the following 48 hours.
- Secondary endpoints include the dose of administered sedatives and analgesics at comparable sedation levels throughout the study, ICU length of stay, and hospital length of stay.
- Limitations are the non-blinded interventions due to the nature of acupuncture.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

73 INTRODUCTION

74 Sedative and analgesic medications are routinely administered to mechanically  
75 ventilated critically ill patients to reduce pain, anxiety, and agitation, as well as to allow  
76 patients to tolerate invasive procedures in the intensive care unit (ICU).<sup>1</sup> Opiates are  
77 most commonly used analgesics, while benzodiazepines, propofol, or dexmedetomidine  
78 are typically used to prevent or reduce anxiety and agitation.<sup>2</sup> However, overuse of these  
79 medications is associated with worsened clinical outcomes, such as prolonged  
80 mechanical ventilation and hospital length of stay, increased risk of altered mental status,  
81 and even higher mortality.<sup>3</sup> Thus, reducing the unnecessary dosage of sedative and  
82 analgesic medications, as well as their side effects while providing desired sedation has  
83 always been a key objective when caring for critically ill patients.

84 As a therapeutic modality with fewer adverse effects, acupuncture has been used in  
85 China and other Asian countries for thousands of years to treat various conditions.<sup>4-6</sup>  
86 Studies of acupuncture usually focuses on its analgesic effect, such as relieving pain and  
87 partly reducing opioid-related side effects during or after surgical procedures.<sup>7-11</sup>  
88 Particularly, the Centers for Medicare & Medicaid Services (CMS) of the USA finalizes  
89 a decision to cover acupuncture for chronic low back pain for Medicare beneficiaries in  
90 January 2020. Moreover, some studies have investigated the use of acupuncture on  
91 reducing sedative and analgesic drug demands, and the duration of mechanical  
92 ventilation, while improving patients' experience during mechanical ventilation.<sup>12-15</sup>  
93 However, there are still a few discrepant research findings on the sedative and analgesic  
94 effects of acupuncture.<sup>16 17</sup> And studies investigating both the sedative and analgesic  
95 effects of acupuncture among all critically ill patients needing mechanical ventilation in  
96 ICU are limited.

97 Therefore, the PASSION study is designed to be an RCT which investigate the efficacy  
98 of acupuncture on sedation and analgesia in mechanically ventilated critically ill  
99 patients. We are going to test the hypothesis that acupuncture, as adjunctive therapy to

sedation and analgesia therapies, could reduce the duration of mechanical ventilation, the dose of administered sedatives and analgesics, and subsequently improve other clinical outcomes for critically ill patients when compared with sham acupuncture or non-acupuncture.

## METHODS

### Study Design Overview

This is a prospective, parallel-group, controlled trial will recruit 180 patients with a computer-generated allocation sequence and centralized randomization at tertiary and regional ICUs in 3 hospitals (Guangdong Provincial Hospital of Chinese Medicine, Charity Hospital of Guangzhou, University Hospital) in South China. Recruitment officially began on 03 November 2021, and the final follow-up of the last subject will not exceed 16 August 2023. Eligible patients will be randomly assigned, in a ratio of 1:1:1, to receive deep needle insertion with combined manual and alternating-mode electrical stimulation on acupoints (AC group, n =60), superficial needle insertion without manual or electrical stimulation on non-acupoints (SAC group, n =60) for 30 min/day, or no acupuncture intervention (NAC group, n =60), respectively.

Participants will be assessed for the duration of mechanical ventilation, as well as the dose of administered sedatives and analgesics at comparable sedation levels, from randomization until patients are free of mechanical ventilation (including noninvasive) without reinstitution for the following 48 hours. They will be also assessed for whether acupuncture can achieve better clinical outcomes than SAC and NAC treatment. The design of the trial is summarized in Figure 1.

### Ethical Requirements and Registration

This protocol is approved by the Institutional Human Clinical Research Ethical Committee at Guangdong Provincial Hospital of Chinese Medicine (Guangzhou, China) in October 2021 with permission number ZF2021-144-01. The PASSION study was

1  
2  
3  
4 126 registered on Nov 3, 2021 (ClinicalTrials.gov, number ChiCTR2100052650) and will  
5  
6 127 be conducted following the Declaration of Helsinki from 03 November 2021 to 16  
7  
8 128 August 2023.

9  
10  
11 129 Written informed consent will be provided before enrollment voluntarily. Considering  
12  
13 130 that patients will be sedated following ICU admission, complete adherence to patient  
14  
15 131 consent is deemed impossible. Patients or their authorized surrogates will be informed  
16  
17 132 by the researchers of the investigational nature and details of the study, together with  
18  
19 133 the possible risks and all the benefits. Written informed consent will be subsequently  
20  
21 134 obtained from either of them. Patients from whom surrogate consent is obtained are  
22  
23 135 asked again to provide informed consent once determined to be competent. They can  
24  
25 136 also withdraw from the study at any time they wish. Also, the investigator can decide to  
26  
27 137 withdraw a subject from the study for urgent medical reasons. The researcher should  
28  
29 138 complete the case report form (CRF) and record the reason for dropping out.

30  
31  
32 139 **Patients**

33  
34 140 Patients from medical and surgical ICU, aging from 18 to 80 years, for expected  
35  
36 141 mechanical ventilation longer than 24 hours, with agitation and/or discomfort after  
37  
38 142 recovering from drugs used to facilitate endotracheal intubation, requiring sedation and  
39  
40 143 agitation by continuous intravenous administration deemed by the ICU physician, are  
41  
42 144 eligible for participation as soon as they or their authorized surrogates are willing to  
43  
44 145 give informed consent (Table 1).

46  
47 146 Exclusion criteria include skin lesions near the acupuncture points, coagulopathy  
48  
49 147 (bleeding time >4 min, thrombocytes <50,000/ $\mu$ l), neurological disease (previous stroke,  
50  
51 148 cerebral palsy, etc.) that would confound the diagnosis of delirium, active seizures,  
52  
53 149 severe dementia, relevant psychiatric disorder, hypohepatia with Childs-Pugh class B  
54  
55 150 or C, second- or third-degree atrioventricular block, alcohol or drug abuse,  
56  
57 151 benzodiazepine dependency, a moribund state with the planned withdrawal of life  
58  
59  
60

support, family or physician refusal, pregnancy or lactation, currently participating in any other investigational therapeutic or device trial (Table 1).

### ICU standard treatment

As a standard in each ICU of our study, mechanically ventilated critically ill patients will be treated in a single treatment room. They will be taken care of by a trained ICU physician responsible for all treatment decisions, including sedation analgesia management plans made in consultation with the bedside nurses. They will also receive one-to-one nursing care to adjust the treatment based on the patient's response in time. A team of medical officers will review patient care every day.

### Randomization and blinding

Eligible patients will be stratified by participating sites to avoid patient-level contamination from the systems-level organizational change in sedation practice and, within each ICU, assigned to the AC, SAC, or NAC group in an equal ratio via computer-generated randomization. In detail, an independent study coordinator will log into the central randomization system using a password-protected account and enter inclusion and exclusion criteria to ensure eligibility. After entering a patient's name and identification card number, a randomization sequence will be generated in blocks of varying sizes and stratified by the site under the control of the central computer system. The random sequence will then be concealed in sealed envelopes and sent to an acupuncturist from the assigned patient's site by the study coordinator.

Allocation of participants will be known to the study coordinator and acupuncturists who will not be involved in outcome assessment and be required to sign a confidentiality agreement about patient allocation. All patients will be treated in a single treatment room. In both AC and SAC groups, patients, bedside nurses, and physicians will be blinded to which acupuncture method the patients will receive. The data collectors and the biostatisticians will be masked from the treatment assignment.



1  
2  
3  
4 178  
5  
6 179  
7  
8 180  
9  
10 181  
11  
12 182  
13  
14 183  
15  
16  
17 184  
18  
19 185  
20  
21 186  
22  
23 187  
24  
25 188  
26  
27 189  
28  
29 190  
30  
31 191  
32  
33 192  
34  
35 193  
36  
37 194  
38  
39 195  
40  
41 196  
42  
43 197  
44  
45  
46 198  
47  
48 199  
49  
50 200  
51  
52 201  
53  
54 202  
55  
56  
57  
58  
59  
60

Acupuncture interventions and procedures

The acupuncture interventions will be developed by a consensus of acupuncture experts according to the Standards for Reporting of Controlled Trials in Acupuncture (STRICTA).<sup>18</sup> Patients will be assigned in a ratio of 1:1:1 to AC group (n=60), SAC group (n=60), and NAC group (n=60). Besides, each group shares the same basic Sedation Analgesia Strategy.

For patients in the AC group, 8 disposable sterile acupuncture needles (filiform needles made of stainless steel, Beijing Hanyi Medical Instruments, China) with a length of 40 mm and a diameter of 0.30 mm will be inserted into acupuncture points at Baihui (DU20), Yintang (EX-HN3), and bilateral acupoints of Shenmen (HT7), Hegu (LI4), Taichong (LR3) according to the theory of traditional Chinese medicine. The localization of these points is measured with a unit of *cun*, a traditional Chinese unit of length. One *cun* of a person is defined as the width of the thumb himself, whereas four fingers are defined as 3 *cun*. The insertion will be followed by manual stimulation, a lifting and thrusting technique combined with twirling and rotating the needle sheath to produce a sensation of soreness, numbness, distention, or radiating. This sensation is known as “*Deqi*” and is considered to be indicative of effective needling. Then, alternating-mode electrical stimulation will be given with the parameters: bursts alternating at 2 Hz and 100 Hz every 3 s, with 10-15 mA intensity inducing no discomfort and no muscle contraction.

For patients in the SAC group, superficial needle insertion with a depth of 2 mm and no manual stimulation will be performed for 30 min/day. The same sort of needles with the AC group will be placed 1 cm distant lateral the used acupoints that are not known as AC points. The electrical stimulator will likewise be connected but without electrical stimulation. (Figure 2)



Patients in the NAC group will receive no acupuncture-related intervention during the trial. But they can receive a free 12-session daily acupuncture treatment after completing the study at their convenience.

Each site will be required to have 2 licensed acupuncturists with more than 3 years of experience and specialized training in the acupuncture protocols before starting the study. The acupuncturists will be responsible for the whole acupuncture process but are not further involved in this study.

### Basic Sedation Analgesia Strategy

In this study, diagnosis and therapeutic management of agitation and pain will be prescribed by the physicians responsible for the clinical care of each patient according to recommended guidelines<sup>19</sup>. An interruptive sedation strategy will be adopted by bedside nurses, and sedation levels and pain intensity will be assessed with the Richmond Agitation Sedation Scale (RASS)<sup>20 21</sup>, the Behavioral Pain Scale (BPS), or the Numeric Rating Scale (NRS)<sup>22 23</sup> every 4 h in order to adapt sedatives and analgesics to avoid overuse. Authorized nurses will titrate infusions, including benzodiazepines, propofol, and dexmedetomidine for sedatives and opiates for analgesia, instead of bolus dosing to minimize potential adverse effects.

The sedation analgesia strategy is designed to consider pain treatment before increasing sedatives to minimize the risk of oversedation. The pain will be assessed either by the BPS in patients unable to communicate or by the NRS, a 1-10 numeric rating scale, in those sufficiently oriented and awake to communicate with the medical staff. Efficacy of the study analgesics drug will be defined as the ability to achieve a score < 3 in both of the pain scoring systems above, evaluated by the bedside nurse. Efficacy of the sedative drug will be defined as the ability to achieve a sedation score between -2 and 1, set by the patient's medical team using the RASS (a highly reliable and well-validated sedation scale for use within patients) over time in the ICU.

1  
2  
3  
4 229 Each morning, a daily interruption of sedation (DIS) will be performed at the clinical  
5  
6 230 medical team’s discretion. Major opioid infusions needed for active pain will be  
7  
8 231 continued. Recommended criteria to interrupt sedation are used: no drug-induced  
9  
10 232 paralysis, no intracranial hypertension, no myocardial ischemia in the previous 24 h,  
11  
12 233 primary disease healing in progress, hemodynamic stability, the partial pressure of  
13  
14 234 arterial oxygen  $\geq 60$  mmHg, the fraction of inspired oxygen  $\leq 50\%$ , and positive end-  
15  
16 235 expiratory pressure  $\leq 8$  cmH<sub>2</sub>O. The interruption of continuous sedation will be coupled  
17  
18 236 with an assessment hourly for wakefulness, defined as the RASS score 1 to 4, and the  
19  
20 237 ability to perform at least 3 of the following requests: eye-opening, tracking, hand  
21  
22 238 squeezing, and toe moving. With the criteria recommended, patients will be able to pass  
23  
24 239 the DIS if they can tolerate it for 4 h and keep awakening enough. Then, a spontaneous  
25  
26 240 breathing trial (SBT) will immediately be managed.<sup>24</sup> If patients are insufficient for the  
27  
28 241 DIS, sedatives will be restarted at half the previous dose and then titrated to achieve  
29  
30 242 patient comfort. DIS will be performed the next morning again.

31  
32  
33 243 **Extubation Test**

34  
35  
36 244 Before extubation, patients will be managed with an SBT. During the SBT, without  
37  
38 245 ventilatory support, patients will be allowed to breathe through a ventilatory circuit with  
39  
40 246 8cm H<sub>2</sub>O PSV, 0 PEEP, and unchanged FiO<sub>2</sub> from the mechanical ventilation period  
41  
42 247 leading up to the SBT.<sup>25</sup> The criteria for a successful SBT are respiratory rate between  
43  
44 248 8 and 35 breaths/min, arterial oxygen saturation  $> 88\%$ , less than 20% change in mean  
45  
46 249 arterial pressure or heart rate, no signs of respiratory distress and acute cardiac  
47  
48 250 arrhythmia, no use of accessory muscles, no abdominal paradox, absence of sweating,  
49  
50 251 agitation or impaired vigilance status. Patients will pass the SBT if they complete a 60  
51  
52 252 min trial meeting the criteria, and extubation will be implemented 6 h later. Patients who  
53  
54 253 fail the SBT will be ventilated immediately with the ventilator settings used before the  
55  
56 254 trial, and sedatives will be restarted at half the previous dose and then titrated to achieve  
57  
58 255 patient comfort. The SBT will be managed the next morning again. Extubation will be  
59  
60 256 implemented following standardized criteria, but the decision to extubate remains upon

the authority of the attending physician in charge of the patient. Researchers will not participate in decisions to extubate patients.

The clinical research team will make sure that the overall research protocol, especially the criteria for sedation and definition of successful SBT, is strictly followed by the bedside nurse and medical teams in charge of the patients. Related information will be reported on the clinical research form.

### Assessing Delirium

Delirium will be measured by the bedside nurses according to the Confusion Assessment Method for the ICU (CAM-ICU) until out of ICU or hospital discharge.<sup>26</sup> Patients will be considered in this state if they have a RASS score  $\geq -3$  and a positive CAM-ICU, defined as positive with the symptoms of feature 1, feature 2, and either feature 3 or feature 4 as follows:

Feature 1: acute onset of mental status change or fluctuation of mental status

Feature 2: inattention

Feature 3: disorganized thinking

Feature 4: altered level of consciousness

### Adverse Event Monitoring

Adverse events will also be defined a priori and prospectively monitored. Adverse events associated with acupuncture include bleeding, hematoma, and local infection. Adverse events related to sedation and analgesia include inadequate pain and sedation management (either pain score  $> 4$  and RASS  $> 1$  for 2 consecutive hours or pain and agitation assumed present if receiving neuromuscular blockade), clinically significant iatrogenic withdrawal. Adverse events associated with mechanical ventilation include accidental removal of medical devices, extubation failure (reintubation within 24 hours), pressure ulcers, catheter-associated bloodstream infections, ventilator-associated

1  
2  
3  
4 282 pneumonia. Every day, research personnel will monitor and assess the seriousness of all  
5  
6 283 adverse events and document all details to determine whether the events are related to  
7  
8 284 acupuncture interventions or the study procedure, as well as developing further  
9  
10 285 treatment strategies including whether it is necessary to uncover blindness. A report of  
11  
12 286 all serious, unexpected, and study-related adverse events will be presented to an  
13  
14 287 independent data and safety monitoring board and the institutional review board within  
15  
16 288 7 days of occurrence.

17  
18  
19 289 **Outcomes and Data Collection**

20  
21 290 The primary outcome is the duration of mechanical ventilation, defined as the time from  
22  
23 291 randomization to successful extubation without reinstitution for the following 48 hours.  
24  
25 292 The secondary outcomes will include the dose of administered sedatives and opiate  
26  
27 293 (absolute value as well as indexed value [total drug in mg/kg ÷ total number of hours  
28  
29 294 from the start of infusion to its ultimate discontinuation]) at comparable clinically  
30  
31 295 individualized target sedation goals throughout the study, the duration of ICU length of  
32  
33 296 stay, and hospital length of stay. Additional outcomes include the prevalence and days  
34  
35 297 of delirium in ICU, mortality in ICU and within 28 days after randomization, and the  
36  
37 298 number of ventilator-free days in 28 days.  
38  
39  
40 299 The day of extubation is considered as the day of death for patients who died while still  
41  
42 300 intubated. Censoring for ICU or hospital length analyses occurred at the time of death  
43  
44 301 or study withdrawal. The number of ventilator-free days in 28 days is defined as days  
45  
46 302 alive and not using mechanical ventilation between days 1 and 28. For the 28-day  
47  
48 303 mortality analyses, patients are censored at the time of the last contact alive or at 28  
49  
50 304 days from enrollment, whichever is first.  
51  
52  
53 305 Baseline demographic data will be collected from patients' records by the medical team,  
54  
55 306 including the reason for ICU admission, Acute Physiology and Chronic Health  
56  
57 307 Evaluation (APACHE) II scores and diagnostic classification, Sequential Organ Failure  
58  
59 308 Assessment (SOFA) scores, hematological and blood chemistry data, and clinical data  
60

(detailed information of sedative and analgesic medications administered to the patients before randomization, cardiac safety profile including electrocardiograms and serum troponins, and liver function profile including serum bilirubin and glutamate pyruvate transaminase, etc.). Vital signs such as blood pressure, heart rate, heart rhythm, temperature, and oxygen saturations will be recorded and collected by the bedside nurses, as well as scores of RASS, BPS, NRS, and CAM-ICU. Moreover, adverse events data will also be collected from patients' records. All of data mentioned above will be entered using the double entry method.

### **Patient and public involvement statement**

There is no patient or public involvement in the design, conduct, reporting or dissemination plans of this research.

### **Statistical Analysis**

Statistical power is estimated using the reduction in duration of mechanical ventilation as the primary outcome. According to Carrasco and colleagues, the mean ( $\pm$ standard deviation) time for current sedation is  $54.7 \pm 12.3$  hours.<sup>27</sup> We calculate that a sample size of 48 patients in each group will provide a power of 90% to detect a 15% relative reduction in intubation time at a two-sided significance level of 0.05. With a dropout rate of 20%, the estimated sample size will be 60 patients per group. Thus, a total of 180 patients will be enrolled in the study.

The per-protocol set (PPS), including patients who complete the study without having major protocol violations, is used for the evaluation of clinical outcomes. While the full analysis set (FAS), determined according to the intention-to-treat population (ITT) who undergo randomization except for those who are excluded after randomization, is not only used for evaluation of clinical outcomes but also baseline characteristics to measure the balance of the three groups before intervention. Missing data will be replaced according to the principle of multiple imputation. Continuous data will be presented as median and interquartile range, while categorical data as numbers and proportion.

1  
2  
3  
4 336  
5  
6 337  
7  
8 338  
9  
10 339  
11  
12 340  
13  
14 341  
15  
16 342  
17  
18 343  
19  
20 344  
21  
22 345  
23  
24  
25 346  
26  
27 347  
28  
29 348  
30  
31 349  
32  
33 350  
34  
35  
36 351  
37  
38 352  
39  
40 353  
41  
42 354  
43  
44 355  
45  
46 356  
47  
48 357  
49  
50 358  
51  
52 359  
53  
54 360  
55  
56 361  
57  
58  
59  
60

Normal distribution will be checked by the Kolmogorov test. For continuous variables, normal distributed data will be compared using one-way analysis of variance among three groups, and independent Student's t-test between any of the two groups. While the comparison of non-normally distributed parameters among three groups will be applied by ANOVA (Kruska Wallis), and then the Mann-Whitney U-test between any of the two groups. Categorical data will be compared by using Fisher's exact test or the chi-square test. Other factors that may affect the efficacy will be considered as co-variants for covariance analysis or Cox proportional hazards regression model.  $P \leq 0.05$  will be considered to indicate statistical significance. All analyses will be done with R statistical software, version 4.0.2.

**DISCUSSION**

This prospective trial is designed to provide evidence on the beneficial effect of acupuncture on reducing the duration of mechanical ventilation, avoiding excessive sedation and analgesia, as well as improving clinical outcomes in sedating mechanically ventilated ICU patients.

General analgesia and sedation are necessary for mechanically ventilated critically ill patients. However, overuse of sedative and analgesic medications may cause varying degrees of side effects, like respiratory drive reduction.<sup>28</sup> These side effects are associated with worsened clinical outcomes, such as prolonged mechanical ventilation and hospital length of stay, increased risk of delirium, and even higher mortality.<sup>29 30</sup> With many sophisticated attempts to mitigate this clinical problem, it has thus far been identified that optimizing analgesia and sedation strategy is able to prevent excessive sedation and analgesia and improve the clinical outcome by reducing the duration and dosage of sedative and analgesic medications.<sup>31-33</sup> Thus, it become a key objective to formulate an intensive sedative and analgesic medications strategy when caring for critically ill patients.



The rationale for evaluating the ability of acupuncture on this subject is based on research findings that acupuncture can manage pain relief and facilitate opioid tapering by increasing the  $\mu$ -opioid receptor binding ability and the release of the opioid peptide.<sup>34 35</sup> According to the meta-analysis of acupuncture on pain relief, visual analog scale (VAS) pain scores in the AC group is lower than that in the NAC group [MD=-11.13, 95%CI(-13.59,-8.68), Z=8.9, P < 0.00001], Figure 3A.<sup>36-50</sup> However, there is a substantial heterogeneity of results in these trials ( $I^2 = 70\%$ ). As shown in Figure 3B, heterogeneity decreases ( $I^2 = 14\%$ ) when the studies by Xian Wang and Zheng Lihong are excluded, and the AC group consistently shows a greater pain relief compared to NAC group [MD=-10.92, 95%CI(-12.93,-8.91), Z=10.66, P < 0.00001]. Meanwhile, acupuncture, without adverse effects, has been shown to exert sedation effects in various medical conditions. As it shown in the meta-analysis, with a high heterogeneity( $I^2 = 95\%$ ), the bispectral index (BIS) value in the AC group is also lower than that in the NAC group [MD=-5.82,95%CI (-9.36, -2.27), Z=3.22, P=0.001], Figure 4A.<sup>51-56</sup> As shown in Figure 4B, heterogeneity decreases ( $I^2 = 0\%$ ) when the studies by J. Fleckenstein and Jiheng Chen are excluded, and the AC group consistently shows a better sedative effect compared to NAC group [MD=-3.18,95%CI(-5.53,-0.84),Z=2.66, P < 0.008]. In addition, previous studies have shown that Yintang (EX-HN3) and Shenmen (HT7) have good sedative effects, Hegu (LI4) and Taichong (LR3) have analgesic advantages, while Baihui (DU20) appears both sedative and analgesic effects.<sup>54 57-60</sup> With these promising results, it is meaningful to assess acupuncture as a potential analgesia and sedation strategy in ameliorating the clinical outcomes in mechanically ventilated critically ill patients.

RCT has been recognized as the gold standard for clinical trials since the late 20th century.<sup>61</sup> Another important designed technique to improve the quality of clinical trials is blinding. Over the past several decades, RCT and blinding have been used to avoid bias (selection bias, performance bias, and ascertainment bias) in clinical trials and

1  
2  
3  
4 389 improve the reliability of effects assessment. Sham acupuncture, aiming to blind the  
5  
6 390 participants and control therapeutic components, is designed as a placebo control.  
7  
8 391 However, this acupuncture technique is relatively difficult to fabricate because it should  
9  
10392 be both biologically inert and psychologically indistinguishable.<sup>62</sup> Even previous  
11  
12393 experience of acupuncture feeling might impact the present perception of verum and  
13  
14394 sham acupuncture intervention.

15  
16  
17395 In PASSION study, we utilize a rigorous set of methods to minimize bias, such as  
18  
19396 computer-generated central randomization, parallel control design, and statistical  
20  
21397 analysis according to the intent-to-treat principle. In control design, the superficial  
22  
23398 needle insertion without manual or electrical stimulation at the non-point is applied to  
24  
25399 simulate deep skin penetration in the SAC group, which is used as the most predominant  
26  
27400 type of sham electropuncture method to ensure blinding according to the published  
28  
29401 literature.<sup>63</sup> However, a few studies reported that superficial needle insertion at non-  
30  
31402 acupoints might not be physiologically inert since the locations of points are nearby true  
32  
33403 acupoints.<sup>64 65</sup> Moreover, researchers found that even mechanical non-penetration can  
34  
35404 evoke slight acupressure effects and physiological activity.<sup>66</sup> Both of these factors will  
36  
37405 affect the effect assessment of acupuncture. Thus, the NA group, avoiding all  
38  
39406 therapeutic components, is designed to clarify whether the sham acupuncture can be  
40  
41407 regarded as physiologically inert, as well as compared with the results of the AC group.

42  
43  
44408 A potential limitation of this trial is blinding. Given the nature of acupuncture, the  
45  
46409 patients and members of the medical team in the NA group are impossible to be blinded  
47  
48410 throughout the entire duration of this trial. However, adequate measures will be taken  
49  
50411 to put the patients and medical team members of the other two groups in a masked state.  
51  
52412 For example, we will formulate a set of isolation and secrecy strategies for the study  
53  
54413 coordinator and acupuncturists to achieve satisfactory blinding levels in treatment  
55  
56414 administration. Thus, in both AC and SAC groups, patients and their medical team  
57  
58415 members will be blinded to the patients' acupuncture method. The data collectors and  
59  
60416 the biostatisticians will also be masked from the treatment assignment.



The PASSION study is designed to demonstrate the efficacy of acupuncture on sedation and analgesia in mechanically ventilated critically ill patients. We expect the finding can provide evidence-based recommendations for acupuncture use for sedation and analgesia in critically ill patients with mechanical ventilation.

### **FUNDING STATEMENT:**

This study was funded by National Science Foundation (grant No. 81703877&82074216&82004135), Science and Technology Planning Project of Guangzhou (202102010301), a Featured Innovative Project from Guangdong Provincial Universities (2019KTSCX029), Young Talents Support Project from China Association of Chinese Medicine (2019-QNRC2-C06), Team of prevention and treatment of acute myocardial infarction with Chinese medicine (2019KCXTD009), Foundation of Guangdong Province of CM (20211187&20201142).

### **DISCLAIMER**

The sponsors have had no role in the project development, in the collection of data, in the preparation of this manuscript, nor the decision to publish. The researchers have complete independence from the sources of funding in all aspects of this study.

### **PATIENT CONSENT FOR PUBLICATION**

Consent obtained from parent(s)/guardian(s).

### **PROVENANCE AND PEER REVIEW**

Not commissioned; externally peer reviewed.

### **ETHICS AND DISSEMINATION**

The study was reviewed and approved by Ethics Committee of Guangdong Province Hospital of Chinese Medicine at Guangzhou University of Chinese Medicine (ZF2021-144-01) and performed in accordance with Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (publication No. 85-23, revised 1996).

### **COMPETING INTERESTS STATEMENT**

1  
2  
3  
4 445 All authors declare that they have no conflict of interest.

5  
6 446 **AUTHORS' CONTRIBUTIONS**

7  
8 447 YZ & SM drafted this manuscript; GY, JW & FC made statistical analysis; MZZ made  
9  
10 448 a critical revision of the manuscript and contributed to the rationalization of the study.  
11  
12 449 All authors read and approved the final manuscript.

13  
14 450 **REFERENCE**

For peer review only

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.  
Enseignement Supérieur (ABES).

1. Coursin DB, Skrobik Y. What Is Safe Sedation in the ICU? *New England Journal of Medicine* 2019;380(26):2577-78. doi: 10.1056/NEJMe1906522
2. Subramaniam B, Shankar P, Shaefi S, et al. Effect of Intravenous Acetaminophen vs Placebo Combined With Propofol or Dexmedetomidine on Postoperative Delirium Among Older Patients Following Cardiac Surgery The DEXACET Randomized Clinical Trial. *Jama-Journal of the American Medical Association* 2019;321(7):686-96. doi: 10.1001/jama.2019.0234
3. Shelton KT, Qu J, Bilotta F, et al. Minimizing ICU Neurological Dysfunction with Dexmedetomidine-induced Sleep (MINDDS): protocol for a randomised, double-blind, parallel-arm, placebo-controlled trial. *BMJ Open* 2018;8(4):e020316. doi: 10.1136/bmjopen-2017-020316 [published Online First: 2018/04/22]
4. Zhao L, Li D, Zheng H, et al. Acupuncture as Adjunctive Therapy for Chronic Stable Angina: A Randomized Clinical Trial. *Jama Internal Medicine* 2019;179(10):1388-97. doi: 10.1001/jamainternmed.2019.2407
5. Garcia MK, Meng Z, Rosenthal DI, et al. Effect of True and Sham Acupuncture on Radiation-Induced Xerostomia Among Patients With Head and Neck Cancer: A Randomized Clinical Trial. *Jama Network Open* 2019;2(12):e1916910. doi: 10.1001/jamanetworkopen.2019.16910
6. Pei W, Peng R, Gu Y, et al. Research trends of acupuncture therapy on insomnia in two decades (from 1999 to 2018): a bibliometric analysis. *Bmc Complementary and Alternative Medicine* 2019;19(1):225. doi: 10.1186/s12906-019-2606-5
7. He Y, Guo X, May BH, et al. Clinical Evidence for Association of Acupuncture and Acupressure With Improved Cancer Pain A Systematic Review and Meta-Analysis. *Jama Oncology* 2020;6(2):271-78. doi: 10.1001/jamaoncol.2019.5233
8. Smith CA, Armour M, Zhu X, et al. Acupuncture for dysmenorrhoea. *Cochrane Database of Systematic*

1  
2  
3  
4 472        *Reviews* 2016(4):CD007854. doi: 10.1002/14651858.CD007854.pub3  
5  
6  
7 473    9. Manheimer E, Cheng K, Wieland LS, et al. Acupuncture for hip osteoarthritis. *Cochrane Database of*  
8  
9  
10 474        *Systematic Reviews* 2018(5):CD013010. doi: 10.1002/14651858.Cd013010  
11  
12 475    10. Dingemann J, Plewig B, Baumann I, et al. Acupuncture in posttonsillectomy pain A prospective, double-  
13  
14  
15 476        blinded, randomized, controlled trial. *Hno* 2017;65:73-79. doi: 10.1007/s00106-016-0290-z  
16  
17  
18 477    11. Wu M-S, Chen K-H, Chen IF, et al. The Efficacy of Acupuncture in Post-Operative Pain Management: A  
19  
20 478        Systematic Review and Meta-Analysis. *Plos One* 2016;11(3):e0150367. doi:  
21  
22  
23 479        10.1371/journal.pone.0150367  
24  
25  
26 480    12. Li Y, Li Y, Zhang WC, et al. Effects of acupuncture in Siguan points on man-machine counteraction in  
27  
28  
29 481        respiratory failure patients during mechanical ventilation. *Zhongguo Zhong Xi Yi Jie He Za Zhi*  
30  
31 482        2006;26(10):930-32.  
32  
33  
34 483    13. Tsay SL, Wang JC, Lin KC, et al. Effects of acupressure therapy for patients having prolonged mechanical  
35  
36  
37 484        ventilation support. *J Adv Nurs* 2005;52(2):142-50. doi: 10.1111/j.1365-2648.2005.03576.x [published  
38  
39 485        Online First: 2005/09/17]  
40  
41  
42 486    14. AminiSaman J, Mohammadi S, Karimpour H, et al. Transcutaneous Electrical Nerve Stimulation at the  
43  
44  
45 487        Acupuncture Points to Relieve Pain of Patients Under Mechanical Ventilation: A Randomized Controlled  
46  
47  
48 488        Study. *J Acupunct Meridian Stud* 2018;11(5):290-95. doi: 10.1016/j.jams.2018.06.008 [published  
49  
50 489        Online First: 2018/07/24]  
51  
52  
53 490    15. Yuan SC, Huang XI, Hua SY, et al. Effect of acupuncture on diaphragmatic function in patients with AECOPD  
54  
55  
56 491        typeII respiratory failure evaluated by ultrasound detection. *Zhongguo Zhen Jiu* 2021;41(07):703-10.  
57  
58 492        doi: 10.13703/j.0255-2930.20200606-k0007  
59  
60

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies. Ensignment Supérieur (ABES).

16. Irnich D, Behrens N, Molzen H, et al. Randomised trial of acupuncture compared with conventional massage and "sham" laser acupuncture for treatment of chronic neck pain. *BMJ* 2001;322(7302):1574-8. doi: 10.1136/bmj.322.7302.1574 [published Online First: 2001/06/30]
17. Kong JT, Puetz C, Tian L, et al. Effect of Electroacupuncture vs Sham Treatment on Change in Pain Severity Among Adults With Chronic Low Back Pain: A Randomized Clinical Trial. *JAMA Netw Open* 2020;3(10):e2022787. doi: 10.1001/jamanetworkopen.2020.22787 [published Online First: 2020/10/28]
18. MacPherson H, Altman DG, Hammerschlag R, et al. Revised STandards for Reporting Interventions in Clinical Trials of Acupuncture (STRICTA): extending the CONSORT statement. *Acupuncture in Medicine* 2010;28(2):83-93. doi: 10.1136/aim.2009.001370
19. Barr J, Fraser GL, Puntillo K, et al. Clinical Practice Guidelines for the Management of Pain, Agitation, and Delirium in Adult Patients in the Intensive Care Unit. *Critical Care Medicine* 2013;41(1):263-306. doi: 10.1097/CCM.0b013e3182783b72
20. Ely EW, Truman B, Shintani A, et al. Monitoring sedation status over time in ICU patients - Reliability and validity of the Richmond Agitation-Sedation Scale (RASS). *Jama-Journal of the American Medical Association* 2003;289(22):2983-91. doi: 10.1001/jama.289.22.2983
21. Sessler CN, Gosnell MS, Grap MJ, et al. The Richmond Agitation-Sedation Scale - Validity and reliability in adult intensive care unit patients. *American Journal of Respiratory and Critical Care Medicine* 2002;166(10):1338-44. doi: 10.1164/rccm.2107138
22. Payen JF, Bru O, Bosson JL, et al. Assessing pain in critically ill sedated patients by using a behavioral pain scale. *Critical Care Medicine* 2001;29(12):2258-63. doi: 10.1097/00003246-200112000-00004
23. Chanques G, Viel E, Constantin J-M, et al. The measurement of pain in intensive care unit: Comparison of

1  
2  
3  
4 514 5 self-report intensity scales. *Pain* 2010;151(3):711-21. doi: 10.1016/j.pain.2010.08.039  
5  
6  
7 515 24. Girard TD, Kress JP, Fuchs BD, et al. Efficacy and safety of a paired sedation and ventilator weaning  
8  
9  
10 516 protocol for mechanically ventilated patients in intensive care (Awakening and Breathing Controlled  
11  
12 517 trial): a randomised controlled trial. *Lancet* 2008;371(9607):126-34. doi: 10.1016/s0140-  
13  
14  
15 518 6736(08)60105-1  
16  
17  
18 519 25. Subira C, Hernandez G, Vazquez A, et al. Effect of Pressure Support vs T-Piece Ventilation Strategies  
19  
20 520 During Spontaneous Breathing Trials on Successful Extubation Among Patients Receiving Mechanical  
21  
22  
23 521 Ventilation A Randomized Clinical Trial. *Jama-Journal of the American Medical Association*  
24  
25  
26 522 2019;321(22):2175-82. doi: 10.1001/jama.2019.7234  
27  
28  
29 523 26. Hui D, Frisbee-Hume S, Wilson A, et al. Effect of Lorazepam With Haloperidol vs Haloperidol Alone on  
30  
31 524 Agitated Delirium in Patients With Advanced Cancer Receiving Palliative Care A Randomized Clinical  
32  
33  
34 525 Trial. *Jama-Journal of the American Medical Association* 2017;318(11):1047-56. doi:  
35  
36  
37 526 10.1001/jama.2017.11468  
38  
39 527 27. Carrasco G, Molina R, Costa J, et al. Propofol vs midazolam in short-, medium-, and long-term sedation of  
40  
41  
42 528 critically ill patients. A cost-benefit analysis. *Chest* 1993;103(2):557-64. doi: 10.1378/chest.103.2.557  
43  
44  
45 529 28. Liu L, Wu A-P, Yang Y, et al. Effects of Propofol on Respiratory Drive and Patient-ventilator Synchrony  
46  
47  
48 530 during Pressure Support Ventilation in Postoperative Patients: A Prospective Study. *Chinese Medical*  
49  
50 531 *Journal* 2017;130(10):1155-60. doi: 10.4103/0366-6999.205864  
51  
52  
53 532 29. Kollef MH, Levy NT, Ahrens TS, et al. The use of continuous IV sedation is associated with prolongation of  
54  
55  
56 533 mechanical ventilation. *Chest* 1998;114(2):541-48. doi: 10.1378/chest.114.2.541  
57  
58  
59 534 30. Ouimet S, Kavanagh BP, Gottfried S, et al. Incidence, risk factors and consequences of ICU delirium.  
60

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.  
Enseignement Supérieur (ABES)

- Intensive Care Medicine* 2007;33(1):66-73. doi: 10.1007/s00134-006-0399-8
31. Chanques G, Conseil M, Roger C, et al. Immediate interruption of sedation compared with usual sedation care in critically ill postoperative patients (SOS-Ventilation): a randomised, parallel-group clinical trial. *Lancet Respiratory Medicine* 2017;5(10):795-805. doi: 10.1016/s2213-2600(17)30304-1
32. Mehta S, Burry L, Cook D, et al. Daily Sedation Interruption in Mechanically Ventilated Critically Ill Patients Cared for With a Sedation Protocol A Randomized Controlled Trial. *Jama-Journal of the American Medical Association* 2012;308(19):1985-92. doi: 10.1001/jama.2012.13872
33. Asmussen S, Przkora R, Maybauer DM, et al. Meta-Analysis of Electroacupuncture in Cardiac Anesthesia and Intensive Care. *Journal of Intensive Care Medicine* 2019;34(8):652-61. doi: 10.1177/0885066617708558
34. Harris RE, Zubieta J-K, Scott DJ, et al. Traditional Chinese acupuncture and placebo (sham) acupuncture are differentiated by their effects on mu-opioid receptors (MORs). *Neuroimage* 2009;47(3):1077-85. doi: 10.1016/j.neuroimage.2009.05.083
35. Han JS. Acupuncture: neuropeptide release produced by electrical stimulation of different frequencies. *Trends in Neurosciences* 2003;26(1):17-22. doi: 10.1016/s0166-2236(02)00006-1
36. Wang B, Tang J, White PF, et al. Effect of the intensity of transcutaneous acupoint electrical stimulation on the postoperative analgesic requirement. *Anesth Analg* 1997;85(2):406-13. doi: 10.1097/00000539-199708000-00029 [published Online First: 1997/08/01]
37. Usichenko TI, Dinse M, Hermsen M, et al. Auricular acupuncture for pain relief after total hip arthroplasty - a randomized controlled study. *Pain* 2005;114(3):320-27. doi: 10.1016/j.pain.2004.08.021 [published Online First: 2005/03/22]



38. White P, Lewith G, Prescott P, et al. Acupuncture versus placebo for the treatment of chronic mechanical neck pain: a randomized, controlled trial. *Ann Intern Med* 2004;141(12):911-19. doi: 10.7326/0003-4819-141-12-200412210-00007 [published Online First: 2004/12/22]
39. Gaubeca-Gilarranz A, Fernandez-de-Las-Penas C, Medina-Torres JR, et al. Effectiveness of dry needling of rectus abdominis trigger points for the treatment of primary dysmenorrhoea: a randomised parallel-group trial. *Acupunct Med* 2018;36(5):302-10. doi: 10.1136/acupmed-2017-011566 [published Online First: 2018/05/04]
40. Kennedy S, Baxter GD, Kerr DP, et al. Acupuncture for acute non-specific low back pain: a pilot randomised non-penetrating sham controlled trial. *Complement Ther Med* 2008;16(3):139-46. doi: 10.1016/j.ctim.2007.03.001 [published Online First: 2008/06/07]
41. Lv Y, He H, Xie J, et al. Effects of transcutaneous acupoint electrical stimulation combined with low-dose sufentanil pretreatment on the incidence and severity of etomidate-induced myoclonus: A randomized controlled trial. *Medicine (Baltimore)* 2018;97(23):e10969. doi: 10.1097/MD.00000000000010969 [published Online First: 2018/06/08]
42. Ma W, Bai W, Lin C, et al. Effects of Sanyinjiao (SP6) with electroacupuncture on labour pain in women during labour. *Complement Ther Med* 2011;19 Suppl 1:S13-8. doi: 10.1016/j.ctim.2010.09.001 [published Online First: 2011/01/05]
43. Mavrommatis CI, Argyra E, Vadalouka A, et al. Acupuncture as an adjunctive therapy to pharmacological treatment in patients with chronic pain due to osteoarthritis of the knee: a 3-armed, randomized, placebo-controlled trial. *Pain* 2012;153(8):1720-26. doi: 10.1016/j.pain.2012.05.005 [published Online First: 2012/06/26]



44. Ng SSM, Leung WW, Mak TWC, et al. Electroacupuncture reduces duration of postoperative ileus after laparoscopic surgery for colorectal cancer. *Gastroenterology* 2013;144(2):307-13 e1. doi: 10.1053/j.gastro.2012.10.050 [published Online First: 2012/11/13]
45. Sui M, Jiang N, Yan L, et al. Effect of Electroacupuncture on Shoulder Subluxation in Poststroke Patients with Hemiplegic Shoulder Pain: A Sham-Controlled Study Using Multidimensional Musculoskeletal Ultrasound Assessment. *Pain Res Manag* 2021;2021:5329881. doi: 10.1155/2021/5329881 [published Online First: 2021/11/30]
46. Tabassi KT, Amini P, Mohammadi S, et al. The effect of acupuncture on pain score after open kidney surgery. *J Complement Integr Med* 2015;12(3):241-44. doi: 10.1515/jcim-2014-0071 [published Online First: 2015/04/30]
47. Wang X, Yin X, Guo XT, et al. Effects of the pestle needle therapy, a type of acupoint stimulation, on post-hemorrhoidectomy pain: A randomized controlled trial. *J Integr Med* 2020;18(6):492-98. doi: 10.1016/j.joim.2020.08.001 [published Online First: 2020/08/17]
48. Wong RH, Lee TW, Sihoe AD, et al. Analgesic effect of electroacupuncture in postthoracotomy pain: a prospective randomized trial. *Ann Thorac Surg* 2006;81(6):2031-6. doi: 10.1016/j.athoracsur.2005.12.064 [published Online First: 2006/05/30]
49. Yu X, Zhang F, Chen B. The effect of TEAS on the quality of early recovery in patients undergoing gynecological laparoscopic surgery: a prospective, randomized, placebo-controlled trial. *Trials* 2020;21(1):43. doi: 10.1186/s13063-019-3892-4 [published Online First: 2020/01/10]
50. Zheng LH, Sun H, Wang GN, et al. Effect of transcutaneous electrical acupoint stimulation on nausea and vomiting induced by patient controlled intravenous analgesia with tramadol. *Chin J Integr Med*

1  
2  
3  
4 598 2008;14(1):61-4. doi: 10.1007/s11655-007-9006  
5  
6  
7 599 10.1007/s11655-007-9006-2 [published Online First: 2008/01/26]  
8  
9  
10 600 51. Chen J, Zhang Y, Li X, et al. Efficacy of transcutaneous electrical acupoint stimulation combined with general  
11  
12 601 anesthesia for sedation and postoperative analgesia in minimally invasive lung cancer surgery: A  
13  
14  
15 602 randomized, double-blind, placebo-controlled trial. *Thorac Cancer* 2020;11(4):928-34. doi:  
16  
17  
18 603 10.1111/1759-7714.13343 [published Online First: 2020/02/18]  
19  
20 604 52. Fleckenstein J, Baeumler P, Gurschler C, et al. Acupuncture reduces the time from extubation to 'ready for  
21  
22  
23 605 discharge' from the post anaesthesia care unit: results from the randomised controlled AcuARP trial.  
24  
25  
26 606 *Sci Rep* 2018;8(1):15734. doi: 10.1038/s41598-018-33459-y [published Online First: 2018/10/26]  
27  
28  
29 607 53. Cabrini L, Gioia L, Gemma M, et al. Bispectral index evaluation of the sedative effect of acupuncture in  
30  
31 608 healthy volunteers. *J Clin Monit Comput* 2006;20(5):311-5. doi: 10.1007/s10877-006-9026-z [published  
32  
33  
34 609 Online First: 2006/09/22]  
35  
36  
37 610 54. Zheng X, Meng JB, Fang Q. Electroacupuncture reduces the dose of midazolam monitored by the bispectral  
38  
39 611 index in critically ill patients with mechanical ventilation: an exploratory study. *Acupunct Med*  
40  
41  
42 612 2012;30(2):78-84. doi: 10.1136/acupmed-2011-010095 [published Online First: 2012/03/31]  
43  
44  
45 613 55. Feng X, Li J, Wu L, et al. Effect of combined electroacupuncture and epidural anesthesia in gynecological  
46  
47  
48 614 operation evaluated by bispectral index. *Zhongguo Zhong Xi Yi Jie He Za Zhi* 2010;30(02):150-  
49  
50 615 52.(Chinese).  
51  
52  
53 616 56. Zheng X, Wan L, Gao F, et al. Effect of ear point embedding on plasma and effect site concentrations of  
54  
55  
56 617 propofol-remifentanil in elderly patients after target-controlled induction. *Zhongguo Zhen Jiu*  
57  
58 618 2017;37(08):869-73. Chinese. doi: 10.13703/j.0255-2930.2017.08.017  
59  
60

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies. Ensignement Supérieur (ABES).

57. Lee KC, Chao YC, Lin YP, et al. Effectiveness of Self-administered Acupressure for Family Caregivers of Advanced Cancer Patients With Insomnia: A Randomized Controlled Trial. *Cancer Nurs* 2022;45(1):E1-E9. doi: 10.1097/NCC.0000000000000870 [published Online First: 2020/08/03]
58. Chen QQ, Wei QL, Zhang XH. Effects of electroacupuncture on supplementary analgesia and improvement of adverse reactions induced by dolantin in oocyte retrieval. *Zhongguo Zhen Jiu* 2012;32(12):1113-16.
59. Xiao J, Yi W, Wu L. Effects of electroacupuncture on reducing labor pain and complications in the labor analgesia process of combined spinal-epidural analgesia with patient-controlled epidural analgesia. *Arch Gynecol Obstet* 2019;299(1):123-28. doi: 10.1007/s00404-018-4955-6 [published Online First: 2018/11/15]
60. Chen TY, Zhou J, Wang K, et al. Electroacupuncture Intervention Combined with Anesthetics for Analgesia and Post-surgical Gastrointestinal Recovery in Pneumectomy Patients. *Zhen Ci Yan Jiu* 2019;40(6):461-64.
61. Meldrum ML. A brief history of the randomized controlled trial - From oranges and lemons to the gold standard. *Hematology-Oncology Clinics of North America* 2000;14(4):745-60. doi: 10.1016/s0889-8588(05)70309-9
62. Boutron I, Guittet L, Estellat C, et al. Reporting methods of blinding in randomized trials assessing nonpharmacological treatments. *Plos Medicine* 2007;4(2):370-80. doi: 10.1371/journal.pmed.0040061
63. Chen Z-x, Li Y, Zhang X-g, et al. Sham Electroacupuncture Methods in Randomized Controlled Trials. *Scientific Reports* 2017;7:40837. doi: 10.1038/srep40837
64. Lund I, Lundeberg T. Are minimal, superficial or sham acupuncture procedures acceptable as inert placebo controls? *Acupuncture in medicine : journal of the British Medical Acupuncture Society* 2006;24(1):13-

1  
2  
3  
4 640  
5  
6  
7 641  
8  
9  
10 642  
11  
12 643  
13  
14  
15 644  
16  
17  
18 645  
19  
20 646  
21  
22  
23  
24 647  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

5.

65. Lundeberg T, Lund I, Naslund J, et al. The Emperor's sham - wrong assumption that sham needling is sham. *Acupuncture in Medicine* 2008;26(4):239-42. doi: 10.1136/aim.26.4.239

66. Kim T-H, Lee MS, Alraek T, et al. Acupuncture in sham device controlled trials may not be as effective as acupuncture in the real world: a preliminary network meta-analysis of studies of acupuncture for hot flashes in menopausal women. *Acupuncture in Medicine* 2020;38(1):37-44. doi: 10.1136/acupmed-2018-011671

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies. Enseignement Supérieur (ABES).

**Table 1. Inclusion and exclusion criteria**

A. Inclusion criteria	B. Exclusion criteria
1. Aged 18 years or over and under 80 years;	1. Skin lesions near the acupuncture points;
2. Required mechanical ventilation >24 hours;	2. Coagulopathy (bleeding time >4 min, thrombocytes <50,000/μl;
3. Continuous intravenous administration of sedative and analgesic medications;	3. Hypohepatia with Childs-Pugh class B or C;
4. Willingness to provide informed consent prior to enrollment;	4. Second- or third-degree atrioventricular block;
5. Be able to comply with all follow-up evaluations (in investigator's opinion).	5. Severe dementia;
	6. Psychiatric disorder;
	7. Neurological disease;
	8. Active seizures;
	9. Alcohol or drug abuse;
	10. Benzodiazepine dependency;
	11. Moribund state with the planned withdrawal of life support;
	12. Family or physician refusal;
	13. Pregnancy or lactation;
	14. Currently participated in any other investigational therapeutic or device trial.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Figure legend:

Figure 1. Trial design of PASSION study

Figure 2. Illustration of the sham points

Figure 3. Forest plot of AC group versus NAC group.

Figure 4. Forest plot of AC group versus NAC group.

For peer review only

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.  
Enseignement Supérieur (ABES).




Figure1

543x691mm (72 x 72 DPI)




Figure2

1005x559mm (38 x 38 DPI)






Figure3

199x162mm (300 x 300 DPI)




Figure4

199x101mm (300 x 300 DPI)

# Reporting checklist for protocol of a clinical trial.

Based on the SPIRIT guidelines.

## Instructions to authors

Complete this checklist by entering the page numbers from your manuscript where readers will find each of the items listed below.

Your article may not currently address all the items on the checklist. Please modify your text to include the missing information. If you are certain that an item does not apply, please write "n/a" and provide a short explanation.

Upload your completed checklist as an extra file when you submit to a journal.

In your methods section, say that you used the SPIRIT reporting guidelines, and cite them as:

Chan A-W, Tetzlaff JM, Gøtzsche PC, Altman DG, Mann H, Berlin J, Dickersin K, Hróbjartsson A, Schulz KF, Parulekar WR, Krleža-Jerić K, Laupacis A, Moher D. SPIRIT 2013 Explanation and Elaboration: Guidance for protocols of clinical trials. BMJ. 2013;346:e7586

Reporting Item			Page Number
<b>Administrative information</b>			
Title	<a href="#">#1</a>	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	Page 1, line 1-4.
Trial registration	<a href="#">#2a</a>	Trial identifier and registry name. If not yet registered, name of intended registry	Page 3, line 58; Page 7, line 130.
Trial registration: data set	<a href="#">#2b</a>	All items from the World Health Organization Trial Registration Data Set	n/a
Protocol version	<a href="#">#3</a>	Date and version identifier	n/a
Funding	<a href="#">#4</a>	Sources and types of financial, material, and other support	Page 18, line 427-434.

1	Roles and	<a href="#">#5a</a>	Names, affiliations, and roles of protocol contributors	Page 1;
2	responsibilities:			
3	contributorship			Page 18-
4				19, line
5				444-449.
6				
7				
8	Roles and	<a href="#">#5b</a>	Name and contact information for the trial sponsor	Page 18,
9	responsibilities:			line 427-
10	sponsor contact			434.
11	information			
12				
13	Roles and	<a href="#">#5c</a>	Role of study sponsor and funders, if any, in study	Page 18,
14	responsibilities:		design; collection, management, analysis, and	line 435-
15	sponsor and funder		interpretation of data; writing of the report; and the	438.
16			decision to submit the report for publication, including	
17			whether they will have ultimate authority over any of	
18			these activities	
19				
20				
21				
22				
23				
24	Roles and	<a href="#">#5d</a>	Composition, roles, and responsibilities of the	Page 13,
25	responsibilities:		coordinating centre, steering committee, endpoint	line 290-
26	committees		adjudication committee, data management team, and	292.
27			other individuals or groups overseeing the trial, if	
28			applicable (see Item 21a for data monitoring committee)	
29				
30				
31				
32				
33	<b>Introduction</b>			
34				
35	Background and	<a href="#">#6a</a>	Description of research question and justification for	Page 5,
36	rationale		undertaking the trial, including summary of relevant	line 77-
37			studies (published and unpublished) examining benefits	100.
38			and harms for each intervention	
39				
40				
41				
42	Background and	<a href="#">#6b</a>	Explanation for choice of comparators	Page 6,
43	rationale: choice of			line 106-
44	comparators			107.
45				
46				
47	Objectives	<a href="#">#7</a>	Specific objectives or hypotheses	Page 6,
48				line 103-
49				107.
50				
51				
52				
53	Trial design	<a href="#">#8</a>	Description of trial design including type of trial (eg,	Page 5-6,
54			parallel group, crossover, factorial, single group),	line 101-
55			allocation ratio, and framework (eg, superiority,	103.
56			equivalence, non-inferiority, exploratory)	
57				
58				
59				
60				

## Methods:

### Participants, interventions, and outcomes

Study setting	<a href="#">#9</a>	Description of study settings (eg, community clinic, academic hospital) and list of countries where data will be collected. Reference to where list of study sites can be obtained	Page 6, line 112-113.
Eligibility criteria	<a href="#">#10</a>	Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and individuals who will perform the interventions (eg, surgeons, psychotherapists)	Page 7-8, line 144-157. Page 8, line 159-164; Page 10, line 210-213;
Interventions: description	<a href="#">#11a</a>	Interventions for each group with sufficient detail to allow replication, including how and when they will be administered	Page 9-10, line 188-213;
Interventions: modifications	<a href="#">#11b</a>	Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving / worsening disease)	Page 13, line 286-290;
Interventions: adherence	<a href="#">#11c</a>	Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return; laboratory tests)	Page 8, line 207-209.
Interventions: concomitant care	<a href="#">#11d</a>	Relevant concomitant care and interventions that are permitted or prohibited during the trial	n/a

1	Outcomes	<a href="#">#12</a>	Primary, secondary, and other outcomes, including the	Page 13,
2			specific measurement variable (eg, systolic blood	line 294-
3			pressure), analysis metric (eg, change from baseline,	302;
4			final value, time to event), method of aggregation (eg,	
5			median, proportion), and time point for each outcome.	
6			Explanation of the clinical relevance of chosen efficacy	
7			and harm outcomes is strongly recommended	
8				
9				
10				
11				
12	Participant timeline	<a href="#">#13</a>	Time schedule of enrolment, interventions (including any	Page 9,
13			run-ins and washouts), assessments, and visits for	line183-
14			participants. A schematic diagram is highly	187.
15			recommended (see Figure)	
16				
17				
18				
19				
20	Sample size	<a href="#">#14</a>	Estimated number of participants needed to achieve	Page 14,
21			study objectives and how it was determined, including	line 325-
22			clinical and statistical assumptions supporting any	331;
23			sample size calculations	
24				
25				
26				
27	Recruitment	<a href="#">#15</a>	Strategies for achieving adequate participant enrolment	Page 14,
28			to reach target sample size	line 330-
29				331.
30				
31				
32				
33				
34				
35	<b>Methods:</b>			
36	<b>Assignment of</b>			
37	<b>interventions (for</b>			
38	<b>controlled trials)</b>			
39				
40				
41				
42	Allocation: sequence	<a href="#">#16a</a>	Method of generating the allocation sequence (eg,	Page 8,
43	generation		computer-generated random numbers), and list of any	line 166-
44			factors for stratification. To reduce predictability of a	175.
45			random sequence, details of any planned restriction (eg,	
46			blocking) should be provided in a separate document	
47			that is unavailable to those who enrol participants or	
48			assign interventions	
49				
50				
51				
52				
53	Allocation	<a href="#">#16b</a>	Mechanism of implementing the allocation sequence (eg,	Page 8,
54	concealment		central telephone; sequentially numbered, opaque,	line 166-
55	mechanism		sealed envelopes), describing any steps to conceal the	175.
56			sequence until interventions are assigned	
57				
58				
59				
60				



Allocation: implementation	<a href="#">#16c</a>	Who will generate the allocation sequence, who will enrol participants, and who will assign participants to interventions	Page 8, line 169-175.
Blinding (masking)	<a href="#">#17a</a>	Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome assessors, data analysts), and how	Page 8, line 179-181.
Blinding (masking): emergency unblinding	<a href="#">#17b</a>	If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant's allocated intervention during the trial	Page 13, line 286-290.
<b>Methods: Data collection, management, and analysis</b>			
Data collection plan	<a href="#">#18a</a>	Plans for assessment and collection of outcome, baseline, and other trial data, including any related processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol	Page 13-14, line 309-320.
Data collection plan: retention	<a href="#">#18b</a>	Plans to promote participant retention and complete follow-up, including list of any outcome data to be collected for participants who discontinue or deviate from intervention protocols	Page 10, line 207-209.
Data management	<a href="#">#19</a>	Plans for data entry, coding, security, and storage, including any related processes to promote data quality (eg, double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol	Page 14, line 320
Statistics: outcomes	<a href="#">#20a</a>	Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the	Page 14-15, line

1		statistical analysis plan can be found, if not in the	332-349.
2		protocol	
3			
4			
5	Statistics: additional	<a href="#">#20b</a> Methods for any additional analyses (eg, subgroup and	Page14,
6	analyses	adjusted analyses)	line 337-
7			338.
8			
9			
10			
11			
12	Statistics: analysis	<a href="#">#20c</a> Definition of analysis population relating to protocol non-	Page14,
13	population and	adherence (eg, as randomised analysis), and any	line 337-
14	missing data	statistical methods to handle missing data (eg, multiple	338.
15		imputation)	
16			
17			
18			
19	<b>Methods: Monitoring</b>		
20			
21	Data monitoring:	<a href="#">#21a</a> Composition of data monitoring committee (DMC);	Page13,
22	formal committee	summary of its role and reporting structure; statement of	line 290-
23		whether it is independent from the sponsor and	292.
24		competing interests; and reference to where further	
25		details about its charter can be found, if not in the	
26		protocol. Alternatively, an explanation of why a DMC is	
27		not needed	
28			
29			
30			
31			
32			
33	Data monitoring:	<a href="#">#21b</a> Description of any interim analyses and stopping	n/a
34	interim analysis	guidelines, including who will have access to these	
35		interim results and make the final decision to terminate	
36		the trial	
37			
38			
39			
40	Harms	<a href="#">#22</a> Plans for collecting, assessing, reporting, and managing	Page12,
41		solicited and spontaneously reported adverse events	line 286-
42		and other unintended effects of trial interventions or trial	292.
43		conduct	
44			
45			
46			
47	Auditing	<a href="#">#23</a> Frequency and procedures for auditing trial conduct, if	n/a
48		any, and whether the process will be independent from	
49		investigators and the sponsor	
50			
51			
52	<b>Ethics and</b>		
53	<b>dissemination</b>		
54			
55			
56	Research ethics	<a href="#">#24</a> Plans for seeking research ethics committee /	Page 6-7,
57	approval	institutional review board (REC / IRB) approval	line127-
58			129.
59			
60			



Protocol amendments	<a href="#">#25</a>	Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC / IRBs, trial participants, trial registries, journals, regulators)	n/a
Consent or assent	<a href="#">#26a</a>	Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32)	Page 7, line135-137.
Consent or assent: ancillary studies	<a href="#">#26b</a>	Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable	n/a
Confidentiality	<a href="#">#27</a>	How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial	Page13-14, line 309-320.
Declaration of interests	<a href="#">#28</a>	Financial and other competing interests for principal investigators for the overall trial and each study site	n/a
Data access	<a href="#">#29</a>	Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators	n/a
Ancillary and post trial care	<a href="#">#30</a>	Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation	n/a
Dissemination policy: trial results	<a href="#">#31a</a>	Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions	n/a
Dissemination policy: authorship	<a href="#">#31b</a>	Authorship eligibility guidelines and any intended use of professional writers	n/a
Dissemination policy: reproducible research	<a href="#">#31c</a>	Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code	n/a

## Appendices

1	Informed consent	<a href="#">#32</a>	Model consent form and other related documentation	n/a
2	materials		given to participants and authorised surrogates	
3				
4				
5	Biological specimens	<a href="#">#33</a>	Plans for collection, laboratory evaluation, and storage of	n/a
6			biological specimens for genetic or molecular analysis in	
7			the current trial and for future use in ancillary studies, if	
8			applicable	
9				
10				

11 None The SPIRIT Explanation and Elaboration paper is distributed under the terms of the Creative  
12 Commons Attribution License CC-BY-NC. This checklist can be completed online using  
13 <https://www.goodreports.org/>, a tool made by the [EQUATOR Network](#) in collaboration with  
14 [Penelope.ai](#)  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

# BMJ Open

## Prospective comparison of acupuncture with sham acupuncture to determine impact on sedation and analgesia in mechanically ventilated critically ill patients (PASSION study): protocol for a randomized controlled trial

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-059741.R2
Article Type:	Protocol
Date Submitted by the Author:	12-Aug-2022
Complete List of Authors:	Zhang, Yuzhuo; Guangzhou University of Chinese Medicine Yang, Guang; Guangzhou University of Chinese Medicine Wei, Jinyi; Guangzhou University of Chinese Medicine Chen, Fangliang; Guangzhou University of Chinese Medicine Zhang, Min-Zhou; Guangzhou University of Chinese Medicine Mao, Shuai; Guangzhou University of Chinese Medicine; Guangdong Provincial Hospital of Chinese Medicine, Department of Critical Care Medicine
<b>Primary Subject Heading</b>:	Intensive care
Secondary Subject Heading:	Complementary medicine
Keywords:	Adult intensive & critical care < ANAESTHETICS, Adult anaesthesia < ANAESTHETICS, Pain management < ANAESTHETICS

SCHOLARONE™  
Manuscripts

1  
2  
3  
4  
5 1 **Prospective comparison of acupuncture with sham acupuncture to**  
6  
7  
8 2 **determine impact on sedation and analgesia in mechanically ventilated**  
9  
10 3 **critically ill patients (PASSION study): Protocol for a randomized**  
11  
12  
13 4 **controlled trial**

15 5 Yuzhuo Zhang, Ph.D. <sup>1\*</sup>

18 6 Guang Yang, M.D. <sup>1,2\*</sup>

20 7 Jinyi Wei, M.D. <sup>1</sup>

23 8 Fangliang Chen, M.D. <sup>1</sup>

26 9 Minzhou Zhang, M.D. <sup>1,2,3Δ</sup>

30 10 Shuai Mao, M.D. <sup>1,2,3Δ</sup>

33 11 *<sup>1</sup> Second Clinical College, Guangzhou University of Chinese Medicine, Guangzhou*  
34 12 *510405, China*

36 13 *<sup>2</sup> Department of Critical Care Medicine, Guangdong Provincial Hospital of Chinese*  
37 14 *Medicine, Guangzhou 510120, China*

39 15 *<sup>3</sup> Guangdong Provincial Branch of National Clinical Research Centre for Chinese*  
40 16 *Medicine Cardiology, Guangzhou 510120, China*

44 18 \*The first two authors contribute equally to this article.

46 19 ΔCorrespondence to:

48 20 Prof. Shuai MAO

50 21 Department of Critical Care Medicine,

52 22 Guangdong Provincial Hospital of Chinese Medicine,

53 23 Guangzhou 510120, China

55 24 Phone: 86-20-81887233

56 25 Fax: 86-20-81867705

58 26 E-mail: [maoshuai@gzucm.edu.cn](mailto:maoshuai@gzucm.edu.cn)

59 27 Or Prof. Minzhou Zhang [minzhouzhang@gzucm.edu.cn](mailto:minzhouzhang@gzucm.edu.cn)

## ABSTRACT

**Introduction** Sedation and analgesia are recommended to be employed in the intensive care unit (ICU) to enhance patient comfort and safety, facilitate mechanical ventilation, and reduce oxygen demands. However, the increasing evidence demonstrates that excessive sedation and analgesia might prolong mechanical ventilation and increase costs and mortality. Acupuncture is known to be able to attenuate pain, anxiety, and agitation symptoms while avoiding excessive sedation and analgesia caused by drugs. Therefore, we present a protocol to investigate whether acupuncture, used for sedation and analgesia, can reduce the duration of mechanical ventilation, save medical resources, and reduce the mortality of critically ill patients receiving mechanical ventilation.

**Methods and analysis** Prospective, randomized controlled trial (RCT) is conducted on 180 adult medical/surgical ICU patients with mechanical ventilation needing sedation at 3 ICUs between 03 November 2021 and 16 August 2023. Patients will be treated with analgesia and sedation to achieve desired target sedation levels (Richmond Agitation Sedation Score of -2 to 1). Enrolled patients will be randomly assigned in a ratio of 1:1:1 to receive deep needle insertion with combined manual and alternating-mode electrical stimulation on acupoints (AC group), superficial needle insertion without manual stimulation and electrical stimulation on non-acupoints (SAC group), or no acupuncture intervention (NAC group).

The primary outcome is the duration of mechanical ventilation from randomization until patients are free of mechanical ventilation (including noninvasive) without reinstitution for the following 48 hours. Secondary endpoints include the dose of administered sedatives and analgesic at comparable sedation levels throughout the study, ICU length of stay, hospital length of stay. Additional outcomes include the prevalence and days of delirium in ICU, mortality in ICU and within 28 days after randomization, and the number of ventilator free days in 28 days.

1

2

3

4 54 **Ethics and dissemination** This trial was approved by the ethics committee at

5

6 55 Guangdong Provincial Hospital of Chinese Medicine. We will publish the study results.

7

8 56 **Trial Registration numbers: ChiCTR2100052650**

9

10

11 57 **Keywords:**

12

13

14 58 acupuncture; sedation; analgesia; critically ill patients; nonpharmacological therapy

15

16 59 **Word Count: 3815**

17

18 60

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

## Strengths and limitations of this study

- This study is an RCT to investigate both the sedative and analgesic effects of acupuncture on critically ill patients needing mechanical ventilation in ICU.
- This study provides a sedative and analgesic strategy for mechanically ventilated critically ill patients with less side effects.
- The primary endpoint is the duration of mechanical ventilation from randomization until patients are free of mechanical ventilation (including noninvasive) without reinstitution for the following 48 hours.
- Secondary endpoints include the dose of administered sedatives and analgesics at comparable sedation levels throughout the study, ICU length of stay, and hospital length of stay.
- Limitations are the non-blinded interventions due to the nature of acupuncture.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

73 INTRODUCTION

74 Sedative and analgesic medications are routinely administered to mechanically  
75 ventilated critically ill patients to reduce pain, anxiety, and agitation, as well as to allow  
76 patients to tolerate invasive procedures in the intensive care unit (ICU).<sup>1</sup> Opiates are  
77 most commonly used analgesics, while benzodiazepines, propofol, or dexmedetomidine  
78 are typically used to prevent or reduce anxiety and agitation.<sup>2</sup> However, overuse of these  
79 medications is associated with worsened clinical outcomes, such as prolonged  
80 mechanical ventilation and hospital length of stay, increased risk of altered mental status,  
81 and even higher mortality.<sup>3</sup> Thus, reducing the unnecessary dosage of sedative and  
82 analgesic medications, as well as their side effects while providing desired sedation has  
83 always been a key objective when caring for critically ill patients.

84 As a therapeutic modality with fewer adverse effects, acupuncture has been used in  
85 China and other Asian countries for thousands of years to treat various conditions.<sup>4-6</sup>  
86 Studies of acupuncture usually focuses on its analgesic effect, such as relieving pain and  
87 partly reducing opioid-related side effects during or after surgical procedures.<sup>7-11</sup>  
88 Particularly, the Centers for Medicare & Medicaid Services (CMS) of the USA finalizes  
89 a decision to cover acupuncture for chronic low back pain for Medicare beneficiaries in  
90 January 2020. Moreover, some studies have investigated the use of acupuncture on  
91 reducing sedative and analgesic drug demands, and the duration of mechanical  
92 ventilation, while improving patients' experience during mechanical ventilation.<sup>12-15</sup>  
93 However, there are still a few discrepant research findings on the sedative and analgesic  
94 effects of acupuncture.<sup>16 17</sup> And studies investigating both the sedative and analgesic  
95 effects of acupuncture among all critically ill patients needing mechanical ventilation in  
96 ICU are limited.

97 Therefore, the PASSION study is designed to be an RCT which investigate the efficacy  
98 of acupuncture on sedation and analgesia in mechanically ventilated critically ill  
99 patients. We are going to test the hypothesis that acupuncture, as adjunctive therapy to



sedation and analgesia therapies, could reduce the duration of mechanical ventilation, the dose of administered sedatives and analgesics, and subsequently improve other clinical outcomes for critically ill patients when compared with sham acupuncture or non-acupuncture.

## METHODS

### Study Design Overview

This is a prospective, parallel-group, controlled trial will recruit 180 patients with a computer-generated allocation sequence and centralized randomization at tertiary and regional ICUs in 3 hospitals (Guangdong Provincial Hospital of Chinese Medicine, Charity Hospital of Guangzhou, University Hospital) in South China. Recruitment officially began on 03 November 2021, and the final follow-up of the last subject will not exceed 16 August 2023. Eligible patients will be randomly assigned, in a ratio of 1:1:1, to receive deep needle insertion with combined manual and alternating-mode electrical stimulation on acupoints (AC group, n =60), superficial needle insertion without manual or electrical stimulation on non-acupoints (SAC group, n =60) for 30 min/day, or no acupuncture intervention (NAC group, n =60), respectively.

Participants will be assessed for the duration of mechanical ventilation, as well as the dose of administered sedatives and analgesics at comparable sedation levels, from randomization until patients are free of mechanical ventilation (including noninvasive) without reinstitution for the following 48 hours. They will be also assessed for whether acupuncture can achieve better clinical outcomes than SAC and NAC treatment. The design of the trial is summarized in Figure 1.

### Ethical Requirements and Registration

This protocol is approved by the Institutional Human Clinical Research Ethical Committee at Guangdong Provincial Hospital of Chinese Medicine (Guangzhou, China) in October 2021 with permission number ZF2021-144-01. The PASSION study was

1  
2  
3  
4 126 registered on Nov 3, 2021 (ClinicalTrials.gov, number ChiCTR2100052650) and will  
5  
6 127 be conducted following the Declaration of Helsinki from 03 November 2021 to 16  
7  
8 128 August 2023.

9  
10  
11 129 Written informed consent will be provided before enrollment voluntarily. Considering  
12  
13 130 that patients will be sedated following ICU admission, complete adherence to patient  
14  
15 131 consent is deemed impossible. Patients or their authorized surrogates will be informed  
16  
17 132 by the researchers of the investigational nature and details of the study, together with  
18  
19 133 the possible risks and all the benefits. Written informed consent will be subsequently  
20  
21 134 obtained from either of them. Patients from whom surrogate consent is obtained are  
22  
23 135 asked again to provide informed consent once determined to be competent. They can  
24  
25 136 also withdraw from the study at any time they wish. Also, the investigator can decide to  
26  
27 137 withdraw a subject from the study for urgent medical reasons. The researcher should  
28  
29 138 complete the case report form (CRF) and record the reason for dropping out.

30  
31  
32 139 **Patients**

33  
34 140 Patients from medical and surgical ICU, aging from 18 to 80 years, for expected  
35  
36 141 mechanical ventilation longer than 24 hours, with agitation and/or discomfort after  
37  
38 142 recovering from drugs used to facilitate endotracheal intubation, requiring sedation and  
39  
40 143 agitation by continuous intravenous administration deemed by the ICU physician, are  
41  
42 144 eligible for participation as soon as they or their authorized surrogates are willing to  
43  
44 145 give informed consent (Table 1).

46  
47 146 **Table 1. Inclusion and exclusion criteria**

A. Inclusion criteria		B. Exclusion criteria	
1. Aged 18 years or over and under 80 years;		1. Skin lesions near the acupuncture points;	
2. Required mechanical ventilation >24 hours;		2. Coagulopathy (bleeding time >4 min, thrombocytes <50,000/μl;	
3. Continuous intravenous administration of sedative and analgesic medications;		3. Hypohepatia with Childs-Pugh class B or C;	

4. Willingness to provide informed consent prior to enrollment;	4. Second- or third-degree atrioventricular block;
5. Be able to comply with all follow-up evaluations (in investigator's opinion).	5. Severe dementia;
	6. Psychiatric disorder;
	7. Neurological disease;
	8. Active seizures;
	9. Alcohol or drug abuse;
	10. Benzodiazepine dependency;
	11. Moribund state with the planned withdrawal of life support;
	12. Family or physician refusal;
	13. Pregnancy or lactation;
	14. Currently participated in any other investigational therapeutic or device trial.

Exclusion criteria include skin lesions near the acupuncture points, coagulopathy (bleeding time >4 min, thrombocytes <50,000/ $\mu$ l), neurological disease (previous stroke, cerebral palsy, etc.) that would confound the diagnosis of delirium, active seizures, severe dementia, relevant psychiatric disorder, hypohepatia with Childs-Pugh class B or C, second- or third-degree atrioventricular block, alcohol or drug abuse, benzodiazepine dependency, a moribund state with the planned withdrawal of life support, family or physician refusal, pregnancy or lactation, currently participating in any other investigational therapeutic or device trial (Table 1).

### ICU standard treatment

As a standard in each ICU of our study, mechanically ventilated critically ill patients will be treated in a single treatment room. They will be taken care of by a trained ICU physician responsible for all treatment decisions, including sedation analgesia management plans made in consultation with the bedside nurses. They will also receive one-to-one nursing care to adjust the treatment based on the patient's response in time. A team of medical officers will review patient care every day.

### Randomization and blinding

1  
2  
3  
4 163 Eligible patients will be stratified by participating sites to avoid patient-level  
5  
6 164 contamination from the systems-level organizational change in sedation practice and,  
7  
8 165 within each ICU, assigned to the AC, SAC, or NAC group in an equal ratio via  
9  
10 166 computer-generated randomization. In detail, an independent study coordinator will log  
11  
12 167 into the central randomization system using a password-protected account and enter  
13  
14 168 inclusion and exclusion criteria to ensure eligibility. After entering a patient's name and  
15  
16 169 identification card number, a randomization sequence will be generated in blocks of  
17  
18 170 varying sizes and stratified by the site under the control of the central computer system.  
19  
20 171 The random sequence will then be concealed in sealed envelopes and sent to an  
21  
22 172 acupuncturist from the assigned patient's site by the study coordinator.

23  
24  
25 173 Allocation of participants will be known to the study coordinator and acupuncturists  
26  
27 174 who will not be involved in outcome assessment and be required to sign a confidentiality  
28  
29 175 agreement about patient allocation. All patients will be treated in a single treatment  
30  
31 176 room. In both AC and SAC groups, patients, bedside nurses, and physicians will be  
32  
33 177 blinded to which acupuncture method the patients will receive. The data collectors and  
34  
35 178 the biostatisticians will be masked from the treatment assignment.

36  
37  
38 179 **Acupuncture interventions and procedures**

39  
40 180 The acupuncture interventions will be developed by a consensus of acupuncture experts  
41  
42 181 according to the Standards for Reporting of Controlled Trials in Acupuncture  
43  
44 182 (STRICTA).<sup>18</sup> Patients will be assigned in a ratio of 1:1:1 to AC group (n=60), SAC  
45  
46 183 group (n=60), and NAC group (n=60). Besides, each group shares the same basic  
47  
48 184 Sedation Analgesia Strategy.

49  
50  
51 185 For patients in the AC group, 8 disposable sterile acupuncture needles (filiform needles  
52  
53 186 made of stainless steel, Beijing Hanyi Medical Instruments, China) with a length of 40  
54  
55 187 mm and a diameter of 0.30 mm will be inserted into acupuncture points at Baihui  
56  
57 188 (DU20), Yintang (EX-HN3), and bilateral acupoints of Shenmen (HT7), Hegu (LI4),  
58  
59 189 Taichong (LR3) according to the theory of traditional Chinese medicine. The  
60

1  
2  
3  
4 190 localization of these points is measured with a unit of *cun*, a traditional Chinese unit of  
5  
6 191 length. One *cun* of a person is defined as the width of the thumb himself, whereas four  
7  
8 192 fingers are defined as 3 *cun*. The insertion will be followed by manual stimulation, a  
9  
10 193 lifting and thrusting technique combined with twirling and rotating the needle sheath to  
11  
12 194 produce a sensation of soreness, numbness, distention, or radiating. This sensation is  
13  
14 195 known as “*Deqi*” and is considered to be indicative of effective needling. Then,  
15  
16 196 alternating-mode electrical stimulation will be given with the parameters: bursts  
17  
18 197 alternating at 2 Hz and 100 Hz every 3 s, with 10-15 mA intensity inducing no  
19  
20 198 discomfort and no muscle contraction.

21  
22  
23 199 For patients in the SAC group, superficial needle insertion with a depth of 2 mm and no  
24  
25 200 manual stimulation will be performed for 30 min/day. The same sort of needles with the  
26  
27 201 AC group will be placed 1 cm distant lateral the used acupoints that are not known as  
28  
29 202 AC points. The electrical stimulator will likewise be connected but without electrical  
30  
31 203 stimulation. (Figure 2)

32  
33  
34 204 Patients in the NAC group will receive no acupuncture-related intervention during the  
35  
36 205 trial. But they can receive a free 12-session daily acupuncture treatment after completing  
37  
38 206 the study at their convenience.

39  
40 207 Each site will be required to have 2 licensed acupuncturists with more than 3 years of  
41  
42 208 experience and specialized training in the acupuncture protocols before starting the  
43  
44 209 study. The acupuncturists will be responsible for the whole acupuncture process but are  
45  
46 210 not further involved in this study.

### 48 49 211 **Basic Sedation Analgesia Strategy**

50  
51  
52 212 In this study, diagnosis and therapeutic management of agitation and pain will be  
53  
54 213 prescribed by the physicians responsible for the clinical care of each patient according  
55  
56 214 to recommended guidelines<sup>19</sup>. An interruptive sedation strategy will be adopted by  
57  
58 215 bedside nurses, and sedation levels and pain intensity will be assessed with the  
59  
60 216 Richmond Agitation Sedation Scale (RASS)<sup>20 21</sup>, the Behavioral Pain Scale (BPS), or

1  
2  
3  
4 217 the Numeric Rating Scale (NRS) <sup>22 23</sup> every 4 h in order to adapt sedatives and analgesics  
5  
6 218 to avoid overuse. Authorized nurses will titrate infusions, including benzodiazepines,  
7  
8 219 propofol, and dexmedetomidine for sedatives and opiates for analgesia, instead of bolus  
9  
10 220 dosing to minimize potential adverse effects.  
11  
12  
13 221 The sedation analgesia strategy is designed to consider pain treatment before increasing  
14  
15 222 sedatives to minimize the risk of oversedation. The pain will be assessed either by the  
16  
17 223 BPS in patients unable to communicate or by the NRS, a 1-10 numeric rating scale, in  
18  
19 224 those sufficiently oriented and awake to communicate with the medical staff. Efficacy  
20  
21 225 of the study analgesics drug will be defined as the ability to achieve a score < 3 in both  
22  
23 226 of the pain scoring systems above, evaluated by the bedside nurse. Efficacy of the  
24  
25 227 sedative drug will be defined as the ability to achieve a sedation score between -2 and  
26  
27 228 1, set by the patient's medical team using the RASS (a highly reliable and well-validated  
28  
29 229 sedation scale for use within patients) over time in the ICU.  
30  
31  
32 230 Each morning, a daily interruption of sedation (DIS) will be performed at the clinical  
33  
34 231 medical team's discretion. Major opioid infusions needed for active pain will be  
35  
36 232 continued. Recommended criteria to interrupt sedation are used: no drug-induced  
37  
38 233 paralysis, no intracranial hypertension, no myocardial ischemia in the previous 24 h,  
39  
40 234 primary disease healing in progress, hemodynamic stability, the partial pressure of  
41  
42 235 arterial oxygen  $\geq 60$  mmHg, the fraction of inspired oxygen  $\leq 50\%$ , and positive end-  
43  
44 236 expiratory pressure  $\leq 8$  cmH<sub>2</sub>O. The interruption of continuous sedation will be coupled  
45  
46 237 with an assessment hourly for wakefulness, defined as the RASS score 1 to 4, and the  
47  
48 238 ability to perform at least 3 of the following requests: eye-opening, tracking, hand  
49  
50 239 squeezing, and toe moving. With the criteria recommended, patients will be able to pass  
51  
52 240 the DIS if they can tolerate it for 4 h and keep awakening enough. Then, a spontaneous  
53  
54 241 breathing trial (SBT) will immediately be managed. <sup>24</sup> If patients are insufficient for the  
55  
56 242 DIS, sedatives will be restarted at half the previous dose and then titrated to achieve  
57  
58 243 patient comfort. DIS will be performed the next morning again.  
59  
60



## Extubation Test

Before extubation, patients will be managed with an SBT. During the SBT, without ventilatory support, patients will be allowed to breathe through a ventilatory circuit with 8cm H<sub>2</sub>O PSV, 0 PEEP, and unchanged FiO<sub>2</sub> from the mechanical ventilation period leading up to the SBT.<sup>25</sup> The criteria for a successful SBT are respiratory rate between 8 and 35 breaths/min, arterial oxygen saturation > 88%, less than 20% change in mean arterial pressure or heart rate, no signs of respiratory distress and acute cardiac arrhythmia, no use of accessory muscles, no abdominal paradox, absence of sweating, agitation or impaired vigilance status. Patients will pass the SBT if they complete a 60 min trial meeting the criteria, and extubation will be implemented 6 h later. Patients who fail the SBT will be ventilated immediately with the ventilator settings used before the trial, and sedatives will be restarted at half the previous dose and then titrated to achieve patient comfort. The SBT will be managed the next morning again. Extubation will be implemented following standardized criteria, but the decision to extubate remains upon the authority of the attending physician in charge of the patient. Researchers will not participate in decisions to extubate patients.

The clinical research team will make sure that the overall research protocol, especially the criteria for sedation and definition of successful SBT, is strictly followed by the bedside nurse and medical teams in charge of the patients. Related information will be reported on the clinical research form.

## Assessing Delirium

Delirium will be measured by the bedside nurses according to the Confusion Assessment Method for the ICU (CAM-ICU) until out of ICU or hospital discharge.<sup>26</sup> Patients will be considered in this state if they have a RASS score  $\geq -3$  and a positive CAM-ICU, defined as positive with the symptoms of feature 1, feature 2, and either feature 3 or feature 4 as follows:

Feature 1: acute onset of mental status change or fluctuation of mental status

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Feature 2: inattention

Feature 3: disorganized thinking

Feature 4: altered level of consciousness

**Adverse Event Monitoring**

Adverse events will also be defined a priori and prospectively monitored. Adverse events associated with acupuncture include bleeding, hematoma, and local infection. Adverse events related to sedation and analgesia include inadequate pain and sedation management (either pain score > 4 and RASS > 1 for 2 consecutive hours or pain and agitation assumed present if receiving neuromuscular blockade), clinically significant iatrogenic withdrawal. Adverse events associated with mechanical ventilation include accidental removal of medical devices, extubation failure (reintubation within 24 hours), pressure ulcers, catheter-associated bloodstream infections, ventilator-associated pneumonia. Every day, research personnel will monitor and assess the seriousness of all adverse events and document all details to determine whether the events are related to acupuncture interventions or the study procedure, as well as developing further treatment strategies including whether it is necessary to uncover blindness. A report of all serious, unexpected, and study-related adverse events will be presented to an independent data and safety monitoring board and the institutional review board within 7 days of occurrence.

**Outcomes and Data Collection**

The primary outcome is the duration of mechanical ventilation, defined as the time from randomization to successful extubation without reinstitution for the following 48 hours. The secondary outcomes will include the dose of administered sedatives and opiate (absolute value as well as indexed value [total drug in mg/kg ÷ total number of hours from the start of infusion to its ultimate discontinuation]) at comparable clinically individualized target sedation goals throughout the study, the duration of ICU length of

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.  
Enseignement Supérieur (ABES)



stay, and hospital length of stay. Additional outcomes include the prevalence and days of delirium in ICU, mortality in ICU and within 28 days after randomization, and the number of ventilator-free days in 28 days.

The day of extubation is considered as the day of death for patients who died while still intubated. Censoring for ICU or hospital length analyses occurred at the time of death or study withdrawal. The number of ventilator-free days in 28 days is defined as days alive and not using mechanical ventilation between days 1 and 28. For the 28-day mortality analyses, patients are censored at the time of the last contact alive or at 28 days from enrollment, whichever is first.

Baseline demographic data will be collected from patients' records by the medical team, including the reason for ICU admission, Acute Physiology and Chronic Health Evaluation (APACHE) II scores and diagnostic classification, Sequential Organ Failure Assessment (SOFA) scores, hematological and blood chemistry data, and clinical data (detailed information of sedative and analgesic medications administered to the patients before randomization, cardiac safety profile including electrocardiograms and serum troponins, and liver function profile including serum bilirubin and glutamate pyruvate transaminase, etc.). Vital signs such as blood pressure, heart rate, heart rhythm, temperature, and oxygen saturations will be recorded and collected by the bedside nurses, as well as scores of RASS, BPS, NRS, and CAM-ICU. Moreover, adverse events data will also be collected from patients' records. All of data mentioned above will be entered using the double entry method.

### **Patient and public involvement statement**

There is no patient or public involvement in the design, conduct, reporting or dissemination plans of this research.

### **Statistical Analysis**

1  
2  
3  
4 322 Statistical power is estimated using the reduction in duration of mechanical ventilation  
5  
6 323 as the primary outcome. According to Carrasco and colleagues, the mean ( $\pm$ standard  
7  
8 324 deviation) time for current sedation is  $54.7 \pm 12.3$  hours.<sup>27</sup> We calculate that a sample  
9  
10325 size of 48 patients in each group will provide a power of 90% to detect a 15% relative  
11  
12326 reduction in intubation time at a two-sided significance level of 0.05. With a dropout  
13  
14327 rate of 20%, the estimated sample size will be 60 patients per group. Thus, a total of 180  
15  
16328 patients will be enrolled in the study.

17  
18  
19329 The per-protocol set (PPS), including patients who complete the study without having  
20  
21330 major protocol violations, is used for the evaluation of clinical outcomes. While the full  
22  
23331 analysis set (FAS), determined according to the intention-to-treat population (ITT) who  
24  
25332 undergo randomization except for those who are excluded after randomization, is not  
26  
27333 only used for evaluation of clinical outcomes but also baseline characteristics to measure  
28  
29334 the balance of the three groups before intervention. Missing data will be replaced by  
30  
31335 Markov Chain Monte Carlo (MCMC) method with 5-10 iterations according to the  
32  
33336 principle of multiple imputation. Continuous data will be presented as median and  
34  
35337 interquartile range, while categorical data as numbers and proportion. Normal  
36  
37338 distribution will be checked by the Kolmogorov test. For continuous variables, normal  
38  
39339 distributed data will be compared using one-way analysis of variance among three  
40  
41340 groups, and independent Student's t-test between any of the two groups. While the  
42  
43341 comparison of non-normally distributed parameters among three groups will be applied  
44  
45342 by ANOVA (Kruska Wallis), and then the Mann-Whitney U-test between any of the  
46  
47343 two groups. Categorical data will be compared by using Fisher's exact test or the chi-  
48  
49344 square test. Other factors that may affect the efficacy will be considered as co-variants  
50  
51345 for covariance analysis or Cox proportional hazards regression model.  $P \leq 0.05$  will be  
52  
53346 considered to indicate statistical significance. All analyses will be done with R statistical  
54  
55347 software, version 4.0.2.

57  
58348 **DISCUSSION**  
59  
60

This prospective trial is designed to provide evidence on the beneficial effect of acupuncture on reducing the duration of mechanical ventilation, avoiding excessive sedation and analgesia, as well as improving clinical outcomes in sedating mechanically ventilated ICU patients.

General analgesia and sedation are necessary for mechanically ventilated critically ill patients. However, overuse of sedative and analgesic medications may cause varying degrees of side effects, like respiratory drive reduction.<sup>28</sup> These side effects are associated with worsened clinical outcomes, such as prolonged mechanical ventilation and hospital length of stay, increased risk of delirium, and even higher mortality.<sup>29-30</sup> With many sophisticated attempts to mitigate this clinical problem, it has thus far been identified that optimizing analgesia and sedation strategy is able to prevent excessive sedation and analgesia and improve the clinical outcome by reducing the duration and dosage of sedative and analgesic medications.<sup>31-33</sup> Thus, it become a key objective to formulate an intensive sedative and analgesic medications strategy when caring for critically ill patients.

The rationale for evaluating the ability of acupuncture on this subject is based on research findings that acupuncture can manage pain relief and facilitate opioid tapering by increasing the  $\mu$ -opioid receptor binding ability and the release of the opioid peptide.<sup>34-35</sup> According to the meta-analysis of acupuncture on pain relief, visual analog scale (VAS) pain scores in the AC group is lower than that in the NAC group [MD=-11.13, 95%CI(-13.59,-8.68), Z=8.9, P<0.00001], Figure 3A.<sup>36-50</sup> However, there is a substantial heterogeneity of results in these trials ( $I^2 = 70\%$ ). As shown in Figure 3B, heterogeneity decreases ( $I^2 = 14\%$ ) when the studies by Xian Wang and Zheng Lihong are excluded, and the AC group consistently shows a greater pain relief compared to NAC group [MD=-10.92, 95%CI(-12.93,-8.91), Z=10.66, P<0.00001]. Meanwhile, acupuncture, without adverse effects, has been shown to exert sedation effects in various medical conditions. As it shown in the meta-analysis, with a high heterogeneity( $I^2 =$

1  
2  
3  
4 376 95%), the bispectral index (BIS) value in the AC group is also lower than that in the  
5  
6 377 NAC group [MD=-5.82,95%CI (-9.36, -2.27), Z=3.22, P=0.001], Figure 4A.<sup>51-56</sup> As  
7  
8 378 shown in Figure 4B, heterogeneity decreases ( $I^2 = 0\%$ ) when the studies by J.  
9  
10379 Fleckenstein and Jiheng Chen are excluded, and the AC group consistently shows a  
11  
12380 better sedative effect compared to NAC group [MD=-3.18,95%CI(-5.53,-0.84),Z=2.66,  
13  
14381  $P < 0.008$ ]. In addition, previous studies have shown that Yintang (EX-HN3) and  
15  
16  
17382 Shenmen (HT7) have good sedative effects, Hegu (LI4) and Taichong (LR3) have  
18  
19383 analgesic advantages, while Baihui (DU20) appears both sedative and analgesic  
20  
21384 effects.<sup>54 57-60</sup> With these promising results, it is meaningful to assess acupuncture as a  
22  
23385 potential analgesia and sedation strategy in ameliorating the clinical outcomes in  
24  
25386 mechanically ventilated critically ill patients.

26  
27  
28387 RCT has been recognized as the gold standard for clinical trials since the late 20th  
29  
30388 century.<sup>61</sup> Another important designed technique to improve the quality of clinical trials  
31  
32389 is blinding. Over the past several decades, RCT and blinding have been used to avoid  
33  
34390 bias (selection bias, performance bias, and ascertainment bias) in clinical trials and  
35  
36391 improve the reliability of effects assessment. Sham acupuncture, aiming to blind the  
37  
38392 participants and control therapeutic components, is designed as a placebo control.  
39  
40393 However, this acupuncture technique is relatively difficult to fabricate because it should  
41  
42394 be both biologically inert and psychologically indistinguishable.<sup>62</sup> Even previous  
43  
44395 experience of acupuncture feeling might impact the present perception of verum and  
45  
46396 sham acupuncture intervention.

47  
48  
49397 In PASSION study, we utilize a rigorous set of methods to minimize bias, such as  
50  
51398 computer-generated central randomization, parallel control design, and statistical  
52  
53399 analysis according to the intent-to-treat principle. In control design, the superficial  
54  
55400 needle insertion without manual or electrical stimulation at the non-point is applied to  
56  
57401 simulate deep skin penetration in the SAC group, which is used as the most predominant  
58  
59402 type of sham electropuncture method to ensure blinding according to the published  
60

literature.<sup>63</sup> However, a few studies reported that superficial needle insertion at non-acupoints might not be physiologically inert since the locations of points are nearby true acupoints.<sup>64 65</sup> Moreover, researchers found that even mechanical non-penetration can evoke slight acupressure effects and physiological activity.<sup>66</sup> Both of these factors will affect the effect assessment of acupuncture. Thus, the NA group, avoiding all therapeutic components, is designed to clarify whether the sham acupuncture can be regarded as physiologically inert, as well as compared with the results of the AC group.

A potential limitation of this trial is blinding. Given the nature of acupuncture, the patients and members of the medical team in the NA group are impossible to be blinded throughout the entire duration of this trial. However, adequate measures will be taken to put the patients and medical team members of the other two groups in a masked state. For example, we will formulate a set of isolation and secrecy strategies for the study coordinator and acupuncturists to achieve satisfactory blinding levels in treatment administration. Thus, in both AC and SAC groups, patients and their medical team members will be blinded to the patients' acupuncture method. The data collectors and the biostatisticians will also be masked from the treatment assignment.

The PASSION study is designed to demonstrate the efficacy of acupuncture on sedation and analgesia in mechanically ventilated critically ill patients. We expect the finding can provide evidence-based recommendations for acupuncture use for sedation and analgesia in critically ill patients with mechanical ventilation.

#### **FUNDING STATEMENT:**

This study was funded by National Science Foundation (grant No. 81703877&82074216&82004135), Science and Technology Planning Project of Guangzhou (202102010301).

1  
2  
3  
4 429  
5  
6 430  
7  
8 431  
9  
10 432  
11  
12 433  
13  
14 434  
15  
16 435  
17  
18 436  
19  
20  
21 437  
22  
23  
24 438  
25  
26 439  
27  
28 440  
29  
30 441  
31  
32 442  
33  
34  
35 443  
36  
37 444  
38  
39 445  
40  
41 446  
42  
43 447  
44  
45 448  
46  
47 449  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**DISCLAIMER**

The sponsors have had no role in the project development, in the collection of data, in the preparation of this manuscript, nor the decision to publish. The researchers have complete independence from the sources of funding in all aspects of this study.

**PATIENT CONSENT FOR PUBLICATION**

Consent obtained from parent(s)/guardian(s).

**PROVENANCE AND PEER REVIEW**

Not commissioned; externally peer reviewed.

**ETHICS AND DISSEMINATION**

The study was reviewed and approved by Ethics Committee of Guangdong Province Hospital of Chinese Medicine at Guangzhou University of Chinese Medicine (ZF2021-144-01) and performed in accordance with Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (publication No. 85-23, revised 1996).

**COMPETING INTERESTS STATEMENT**

All authors declare that they have no conflict of interest.

**AUTHORS' CONTRIBUTIONS**

YZ & SM drafted this manuscript; GY, JW & FC made statistical analysis; MZZ made a critical revision of the manuscript and contributed to the rationalization of the study. All authors read and approved the final manuscript.

**REFERENCE**



1. Coursin DB, Skrobik Y. What Is Safe Sedation in the ICU? *New England Journal of Medicine* 2019;380(26):2577-78. doi: 10.1056/NEJMe1906522
2. Subramaniam B, Shankar P, Shaefi S, et al. Effect of Intravenous Acetaminophen vs Placebo Combined With Propofol or Dexmedetomidine on Postoperative Delirium Among Older Patients Following Cardiac Surgery The DEXACET Randomized Clinical Trial. *Jama-Journal of the American Medical Association* 2019;321(7):686-96. doi: 10.1001/jama.2019.0234
3. Shelton KT, Qu J, Bilotta F, et al. Minimizing ICU Neurological Dysfunction with Dexmedetomidine-induced Sleep (MINDDS): protocol for a randomised, double-blind, parallel-arm, placebo-controlled trial. *BMJ Open* 2018;8(4):e020316. doi: 10.1136/bmjopen-2017-020316 [published Online First: 2018/04/22]
4. Zhao L, Li D, Zheng H, et al. Acupuncture as Adjunctive Therapy for Chronic Stable Angina: A Randomized Clinical Trial. *Jama Internal Medicine* 2019;179(10):1388-97. doi: 10.1001/jamainternmed.2019.2407
5. Garcia MK, Meng Z, Rosenthal DI, et al. Effect of True and Sham Acupuncture on Radiation-Induced Xerostomia Among Patients With Head and Neck Cancer: A Randomized Clinical Trial. *Jama Network Open* 2019;2(12):e1916910. doi: 10.1001/jamanetworkopen.2019.16910
6. Pei W, Peng R, Gu Y, et al. Research trends of acupuncture therapy on insomnia in two decades (from 1999 to 2018): a bibliometric analysis. *Bmc Complementary and Alternative Medicine* 2019;19(1):225. doi: 10.1186/s12906-019-2606-5
7. He Y, Guo X, May BH, et al. Clinical Evidence for Association of Acupuncture and Acupressure With Improved Cancer Pain A Systematic Review and Meta-Analysis. *Jama Oncology* 2020;6(2):271-78. doi: 10.1001/jamaoncol.2019.5233
8. Smith CA, Armour M, Zhu X, et al. Acupuncture for dysmenorrhoea. *Cochrane Database of Systematic Reviews* 2016(4):CD007854. doi: 10.1002/14651858.CD007854.pub3
9. Manheimer E, Cheng K, Wieland LS, et al. Acupuncture for hip osteoarthritis. *Cochrane Database of Systematic Reviews* 2018(5):CD013010. doi: 10.1002/14651858.Cd013010
10. Dingemann J, Plewig B, Baumann I, et al. Acupuncture in posttonsillectomy pain A prospective, double-blinded, randomized, controlled trial. *Hno* 2017;65:73-79. doi: 10.1007/s00106-016-0290-z
11. Wu M-S, Chen K-H, Chen IF, et al. The Efficacy of Acupuncture in Post-Operative Pain Management: A Systematic Review and Meta-Analysis. *Plos One* 2016;11(3):e0150367. doi: 10.1371/journal.pone.0150367
12. Li Y, Li Y, Zhang WC, et al. Effects of acupuncture in Siguan points on man-machine counteraction in respiratory failure patients during mechanical ventilation. *Zhongguo Zhong Xi Yi Jie He Za Zhi* 2006;26(10):930-32.
13. Tsay SL, Wang JC, Lin KC, et al. Effects of acupressure therapy for patients having prolonged mechanical ventilation support. *J Adv Nurs* 2005;52(2):142-50. doi: 10.1111/j.1365-2648.2005.03576.x [published Online First: 2005/09/17]
14. AminiSaman J, Mohammadi S, Karimpour H, et al. Transcutaneous Electrical Nerve Stimulation at the Acupuncture Points to Relieve Pain of Patients Under Mechanical Ventilation: A Randomized Controlled Study. *J Acupunct Meridian Stud* 2018;11(5):290-95. doi: 10.1016/j.jams.2018.06.008 [published Online First: 2018/07/24]
15. Yuan SC, Huang XL, Hua SY, et al. Effect of acupuncture on diaphragmatic function in patients with AECOPD type II respiratory failure evaluated by ultrasound detection. *Zhongguo Zhen Jiu* 2021;41(07):703-10. doi: 10.13703/j.0255-2930.20200606-k0007
16. Irnich D, Behrens N, Molzen H, et al. Randomised trial of acupuncture compared with conventional massage and "sham" laser acupuncture for treatment of chronic neck pain. *BMJ* 2001;322(7302):1574-8. doi: 10.1136/bmj.322.7302.1574 [published Online First: 2001/06/30]

1  
2  
3 492 17. Kong JT, Puetz C, Tian L, et al. Effect of Electroacupuncture vs Sham Treatment on Change in Pain Severity Among  
4 493 Adults With Chronic Low Back Pain: A Randomized Clinical Trial. *JAMA Netw Open* 2020;3(10):e2022787. doi:  
5 494 10.1001/jamanetworkopen.2020.22787 [published Online First: 2020/10/28]  
6 495  
7 496 18. MacPherson H, Altman DG, Hammerschlag R, et al. Revised STAndards for Reporting Interventions in Clinical Trials  
8 of Acupuncture (STRICTA): extending the CONSORT statement. *Acupuncture in Medicine* 2010;28(2):83-93.  
9 497 doi: 10.1136/aim.2009.001370  
10 498  
11 499 19. Barr J, Fraser GL, Puntillo K, et al. Clinical Practice Guidelines for the Management of Pain, Agitation, and Delirium  
12 in Adult Patients in the Intensive Care Unit. *Critical Care Medicine* 2013;41(1):263-306. doi:  
13 500 10.1097/CCM.0b013e3182783b72  
14 501  
15 502 20. Ely EW, Truman B, Shintani A, et al. Monitoring sedation status over time in ICU patients - Reliability and validity of  
16 the Richmond Agitation-Sedation Scale (RASS). *Jama-Journal of the American Medical Association*  
17 503 2003;289(22):2983-91. doi: 10.1001/jama.289.22.2983  
18 504  
19 505 21. Sessler CN, Gosnell MS, Grap MJ, et al. The Richmond Agitation-Sedation Scale - Validity and reliability in adult  
20 intensive care unit patients. *American Journal of Respiratory and Critical Care Medicine* 2002;166(10):1338-44.  
21 506 doi: 10.1164/rccm.2107138  
22 507  
23 508 22. Payen JF, Bru O, Bosson JL, et al. Assessing pain in critically ill sedated patients by using a behavioral pain scale.  
24 *Critical Care Medicine* 2001;29(12):2258-63. doi: 10.1097/00003246-200112000-00004  
25 509  
26 510 23. Chanques G, Viel E, Constantin J-M, et al. The measurement of pain in intensive care unit: Comparison of 5 self-report  
27 intensity scales. *Pain* 2010;151(3):711-21. doi: 10.1016/j.pain.2010.08.039  
28 511  
29 512 24. Girard TD, Kress JP, Fuchs BD, et al. Efficacy and safety of a paired sedation and ventilator weaning protocol for  
30 mechanically ventilated patients in intensive care (Awakening and Breathing Controlled trial): a randomised  
31 controlled trial. *Lancet* 2008;371(9607):126-34. doi: 10.1016/s0140-6736(08)60105-1  
32 513  
33 514 25. Subira C, Hernandez G, Vazquez A, et al. Effect of Pressure Support vs T-Piece Ventilation Strategies During  
34 Spontaneous Breathing Trials on Successful Extubation Among Patients Receiving Mechanical Ventilation A  
35 Randomized Clinical Trial. *Jama-Journal of the American Medical Association* 2019;321(22):2175-82. doi:  
36 516 10.1001/jama.2019.7234  
37 517  
38 518 26. Hui D, Frisbee-Hume S, Wilson A, et al. Effect of Lorazepam With Haloperidol vs Haloperidol Alone on Agitated  
39 Delirium in Patients With Advanced Cancer Receiving Palliative Care A Randomized Clinical Trial. *Jama-*  
40 *Journal of the American Medical Association* 2017;318(11):1047-56. doi: 10.1001/jama.2017.11468  
41 520  
42 521 27. Carrasco G, Molina R, Costa J, et al. Propofol vs midazolam in short-, medium-, and long-term sedation of critically  
43 ill patients. A cost-benefit analysis. *Chest* 1993;103(2):557-64. doi: 10.1378/chest.103.2.557  
44 522  
45 523 28. Liu L, Wu A-P, Yang Y, et al. Effects of Propofol on Respiratory Drive and Patient-ventilator Synchrony during  
46 Pressure Support Ventilation in Postoperative Patients: A Prospective Study. *Chinese Medical Journal*  
47 524 2017;130(10):1155-60. doi: 10.4103/0366-6999.205864  
48 525  
49 526 29. Kollef MH, Levy NT, Ahrens TS, et al. The use of continuous IV sedation is associated with prolongation of mechanical  
50 ventilation. *Chest* 1998;114(2):541-48. doi: 10.1378/chest.114.2.541  
51 527  
52 528 30. Ouimet S, Kavanagh BP, Gottfried S, et al. Incidence, risk factors and consequences of ICU delirium. *Intensive Care*  
53 *Medicine* 2007;33(1):66-73. doi: 10.1007/s00134-006-0399-8  
54 529  
55 530 31. Chanques G, Conseil M, Roger C, et al. Immediate interruption of sedation compared with usual sedation care in  
56 critically ill postoperative patients (SOS-Ventilation): a randomised, parallel-group clinical trial. *Lancet*  
57 *Respiratory Medicine* 2017;5(10):795-805. doi: 10.1016/s2213-2600(17)30304-1  
58 532  
59 533 32. Mehta S, Burry L, Cook D, et al. Daily Sedation Interruption in Mechanically Ventilated Critically Ill Patients Cared  
60



- for With a Sedation Protocol A Randomized Controlled Trial. *Jama-Journal of the American Medical Association* 2012;308(19):1985-92. doi: 10.1001/jama.2012.13872
33. Asmussen S, Przkora R, Maybauer DM, et al. Meta-Analysis of Electroacupuncture in Cardiac Anesthesia and Intensive Care. *Journal of Intensive Care Medicine* 2019;34(8):652-61. doi: 10.1177/0885066617708558
34. Harris RE, Zubieta J-K, Scott DJ, et al. Traditional Chinese acupuncture and placebo (sham) acupuncture are differentiated by their effects on mu-opioid receptors (MORs). *Neuroimage* 2009;47(3):1077-85. doi: 10.1016/j.neuroimage.2009.05.083
35. Han JS. Acupuncture: neuropeptide release produced by electrical stimulation of different frequencies. *Trends in Neurosciences* 2003;26(1):17-22. doi: 10.1016/s0166-2236(02)00006-1
36. Wang B, Tang J, White PF, et al. Effect of the intensity of transcutaneous acupoint electrical stimulation on the postoperative analgesic requirement. *Anesth Analg* 1997;85(2):406-13. doi: 10.1097/00000539-199708000-00029 [published Online First: 1997/08/01]
37. Usichenko TI, Dinse M, Hermesen M, et al. Auricular acupuncture for pain relief after total hip arthroplasty - a randomized controlled study. *Pain* 2005;114(3):320-27. doi: 10.1016/j.pain.2004.08.021 [published Online First: 2005/03/22]
38. White P, Lewith G, Prescott P, et al. Acupuncture versus placebo for the treatment of chronic mechanical neck pain: a randomized, controlled trial. *Ann Intern Med* 2004;141(12):911-19. doi: 10.7326/0003-4819-141-12-200412210-00007 [published Online First: 2004/12/22]
39. Gaubeca-Gilarranz A, Fernandez-de-Las-Penas C, Medina-Torres JR, et al. Effectiveness of dry needling of rectus abdominis trigger points for the treatment of primary dysmenorrhoea: a randomised parallel-group trial. *Acupunct Med* 2018;36(5):302-10. doi: 10.1136/acupmed-2017-011566 [published Online First: 2018/05/04]
40. Kennedy S, Baxter GD, Kerr DP, et al. Acupuncture for acute non-specific low back pain: a pilot randomised non-penetrating sham controlled trial. *Complement Ther Med* 2008;16(3):139-46. doi: 10.1016/j.ctim.2007.03.001 [published Online First: 2008/06/07]
41. Lv Y, He H, Xie J, et al. Effects of transcutaneous acupoint electrical stimulation combined with low-dose sufentanil pretreatment on the incidence and severity of etomidate-induced myoclonus: A randomized controlled trial. *Medicine (Baltimore)* 2018;97(23):e10969. doi: 10.1097/MD.00000000000010969 [published Online First: 2018/06/08]
42. Ma W, Bai W, Lin C, et al. Effects of Sanyinjiao (SP6) with electroacupuncture on labour pain in women during labour. *Complement Ther Med* 2011;19 Suppl 1:S13-8. doi: 10.1016/j.ctim.2010.09.001 [published Online First: 2011/01/05]
43. Mavrommatis CI, Argyra E, Vadalouka A, et al. Acupuncture as an adjunctive therapy to pharmacological treatment in patients with chronic pain due to osteoarthritis of the knee: a 3-armed, randomized, placebo-controlled trial. *Pain* 2012;153(8):1720-26. doi: 10.1016/j.pain.2012.05.005 [published Online First: 2012/06/26]
44. Ng SSM, Leung WW, Mak TWC, et al. Electroacupuncture reduces duration of postoperative ileus after laparoscopic surgery for colorectal cancer. *Gastroenterology* 2013;144(2):307-13 e1. doi: 10.1053/j.gastro.2012.10.050 [published Online First: 2012/11/13]
45. Sui M, Jiang N, Yan L, et al. Effect of Electroacupuncture on Shoulder Subluxation in Poststroke Patients with Hemiplegic Shoulder Pain: A Sham-Controlled Study Using Multidimensional Musculoskeletal Ultrasound Assessment. *Pain Res Manag* 2021;2021:5329881. doi: 10.1155/2021/5329881 [published Online First: 2021/11/30]
46. Tabassi KT, Amini P, Mohammadi S, et al. The effect of acupuncture on pain score after open kidney surgery. *J*

1  
2  
3 576 *Complement Integr Med* 2015;12(3):241-44. doi: 10.1515/jcim-2014-0071 [published Online First: 2015/04/30]  
4  
5 577 47. Wang X, Yin X, Guo XT, et al. Effects of the pestle needle therapy, a type of acupoint stimulation, on post-  
6 578 hemorrhoidectomy pain: A randomized controlled trial. *J Integr Med* 2020;18(6):492-98. doi:  
7 579 10.1016/j.joim.2020.08.001 [published Online First: 2020/08/17]  
8  
9 580 48. Wong RH, Lee TW, Sihoe AD, et al. Analgesic effect of electroacupuncture in postthoracotomy pain: a prospective  
10 581 randomized trial. *Ann Thorac Surg* 2006;81(6):2031-6. doi: 10.1016/j.athoracsur.2005.12.064 [published Online  
11 582 First: 2006/05/30]  
12  
13 583 49. Yu X, Zhang F, Chen B. The effect of TEAS on the quality of early recovery in patients undergoing gynecological  
14 584 laparoscopic surgery: a prospective, randomized, placebo-controlled trial. *Trials* 2020;21(1):43. doi:  
15 585 10.1186/s13063-019-3892-4 [published Online First: 2020/01/10]  
16  
17 586 50. Zheng LH, Sun H, Wang GN, et al. Effect of transcutaneous electrical acupoint stimulation on nausea and vomiting  
18 587 induced by patient controlled intravenous analgesia with tramadol. *Chin J Integr Med* 2008;14(1):61-4. doi:  
19 588 10.1007/s11655-007-9006  
20 589 10.1007/s11655-007-9006-2 [published Online First: 2008/01/26]  
21  
22 590 51. Chen J, Zhang Y, Li X, et al. Efficacy of transcutaneous electrical acupoint stimulation combined with general  
23 591 anesthesia for sedation and postoperative analgesia in minimally invasive lung cancer surgery: A randomized,  
24 592 double-blind, placebo-controlled trial. *Thorac Cancer* 2020;11(4):928-34. doi: 10.1111/1759-7714.13343  
25 593 [published Online First: 2020/02/18]  
26  
27 594 52. Fleckenstein J, Baeumler P, Gurschler C, et al. Acupuncture reduces the time from extubation to 'ready for discharge'  
28 595 from the post anaesthesia care unit: results from the randomised controlled AcuARP trial. *Sci Rep*  
29 596 2018;8(1):15734. doi: 10.1038/s41598-018-33459-y [published Online First: 2018/10/26]  
30  
31 597 53. Cabrini L, Gioia L, Gemma M, et al. Bispectral index evaluation of the sedative effect of acupuncture in healthy  
32 598 volunteers. *J Clin Monit Comput* 2006;20(5):311-5. doi: 10.1007/s10877-006-9026-z [published Online First:  
33 599 2006/09/22]  
34  
35 600 54. Zheng X, Meng JB, Fang Q. Electroacupuncture reduces the dose of midazolam monitored by the bispectral index in  
36 601 critically ill patients with mechanical ventilation: an exploratory study. *Acupunct Med* 2012;30(2):78-84. doi:  
37 602 10.1136/acupmed-2011-010095 [published Online First: 2012/03/31]  
38  
39 603 55. Feng X, Li J, Wu L, et al. Effect of combined electroacupuncture and epidural anesthesia in gynecological operation  
40 604 evaluated by bispectral index. *Zhongguo Zhong Xi Yi Jie He Za Zhi* 2010;30(02):150-52.(Chinese).  
41  
42 605 56. Zheng X, Wan L, Gao F, et al. Effect of ear point embedding on plasma and effect site concentrations of propofol-  
43 606 remifentanyl in elderly patients after target-controlled induction. *Zhongguo Zhen Jiu* 2017;37(08):869-73. Chinese.  
44 607 doi: 10.13703/j.0255-2930.2017.08.017  
45  
46 608 57. Lee KC, Chao YC, Lin YP, et al. Effectiveness of Self-administered Acupressure for Family Caregivers of Advanced  
47 609 Cancer Patients With Insomnia: A Randomized Controlled Trial. *Cancer Nurs* 2022;45(1):E1-E9. doi:  
48 610 10.1097/NCC.0000000000000870 [published Online First: 2020/08/03]  
49  
50 611 58. Chen QQ, Wei QL, Zhang XH. Effects of electroacupuncture on supplementary analgesia and improvement of adverse  
51 612 reactions induced by dolantin in oocyte retrieval. *Zhongguo Zhen Jiu* 2012;32(12):1113-16.  
52  
53 613 59. Xiao J, Yi W, Wu L. Effects of electroacupuncture on reducing labor pain and complications in the labor analgesia  
54 614 process of combined spinal-epidural analgesia with patient-controlled epidural analgesia. *Arch Gynecol Obstet*  
55 615 2019;299(1):123-28. doi: 10.1007/s00404-018-4955-6 [published Online First: 2018/11/15]  
56  
57 616 60. Chen TY, Zhou J, Wang K, et al. Electroacupuncture Intervention Combined with Anesthetics for Analgesia and Post-  
58 617 surgical Gastrointestinal Recovery in Pneumectomy Patients. *Zhen Ci Yan Jiu* 2019;40(6):461-64.  
59  
60

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

61. Meldrum ML. A brief history of the randomized controlled trial - From oranges and lemons to the gold standard. *Hematology-Oncology Clinics of North America* 2000;14(4):745-60. doi: 10.1016/s0889-8588(05)70309-9
62. Boutron I, Guittet L, Estellat C, et al. Reporting methods of blinding in randomized trials assessing nonpharmacological treatments. *Plos Medicine* 2007;4(2):370-80. doi: 10.1371/journal.pmed.0040061
63. Chen Z-x, Li Y, Zhang X-g, et al. Sham Electroacupuncture Methods in Randomized Controlled Trials. *Scientific Reports* 2017;7:40837. doi: 10.1038/srep40837
64. Lund I, Lundeberg T. Are minimal, superficial or sham acupuncture procedures acceptable as inert placebo controls? *Acupuncture in medicine : journal of the British Medical Acupuncture Society* 2006;24(1):13-5.
65. Lundeberg T, Lund I, Naslund J, et al. The Emperor's sham - wrong assumption that sham needling is sham. *Acupuncture in Medicine* 2008;26(4):239-42. doi: 10.1136/aim.26.4.239
66. Kim T-H, Lee MS, Alraek T, et al. Acupuncture in sham device controlled trials may not be as effective as acupuncture in the real world: a preliminary network meta-analysis of studies of acupuncture for hot flashes in menopausal women. *Acupuncture in Medicine* 2020;38(1):37-44. doi: 10.1136/acupmed-2018-011671

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Figure legend:

Figure 1. Trial design of PASSION study

Figure 2. Illustration of the sham points

Figure 3. Forest plot of AC group versus NAC group.

Figure 4. Forest plot of AC group versus NAC group.

For peer review only

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.  
Enseignement Supérieur (ABES).




Figure 1

543x691mm (72 x 72 DPI)




Figure 2

398x221mm (96 x 96 DPI)




Figure3

199x162mm (300 x 300 DPI)






Figure4

199x101mm (300 x 300 DPI)

# Reporting checklist for protocol of a clinical trial.

Based on the SPIRIT guidelines.

## Instructions to authors

Complete this checklist by entering the page numbers from your manuscript where readers will find each of the items listed below.

Your article may not currently address all the items on the checklist. Please modify your text to include the missing information. If you are certain that an item does not apply, please write "n/a" and provide a short explanation.

Upload your completed checklist as an extra file when you submit to a journal.

In your methods section, say that you used the SPIRIT reporting guidelines, and cite them as:

Chan A-W, Tetzlaff JM, Gøtzsche PC, Altman DG, Mann H, Berlin J, Dickersin K, Hróbjartsson A, Schulz KF, Parulekar WR, Krleža-Jerić K, Laupacis A, Moher D. SPIRIT 2013 Explanation and Elaboration: Guidance for protocols of clinical trials. BMJ. 2013;346:e7586

Reporting Item			Page Number
<b>Administrative information</b>			
Title	<a href="#">#1</a>	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	Page 1, line 1-4.
Trial registration	<a href="#">#2a</a>	Trial identifier and registry name. If not yet registered, name of intended registry	Page 3, line 58; Page 7, line 130.
Trial registration: data set	<a href="#">#2b</a>	All items from the World Health Organization Trial Registration Data Set	n/a
Protocol version	<a href="#">#3</a>	Date and version identifier	n/a
Funding	<a href="#">#4</a>	Sources and types of financial, material, and other support	Page 18, line 427-434.

1	Roles and	<a href="#">#5a</a>	Names, affiliations, and roles of protocol contributors	Page 1;
2	responsibilities:			
3	contributorship			Page 18-
4				19, line
5				444-449.
6				
7				
8	Roles and	<a href="#">#5b</a>	Name and contact information for the trial sponsor	Page 18,
9	responsibilities:			line 427-
10	sponsor contact			434.
11	information			
12				
13	Roles and	<a href="#">#5c</a>	Role of study sponsor and funders, if any, in study	Page 18,
14	responsibilities:		design; collection, management, analysis, and	line 435-
15	sponsor and funder		interpretation of data; writing of the report; and the	438.
16			decision to submit the report for publication, including	
17			whether they will have ultimate authority over any of	
18			these activities	
19				
20				
21				
22				
23				
24	Roles and	<a href="#">#5d</a>	Composition, roles, and responsibilities of the	Page 13,
25	responsibilities:		coordinating centre, steering committee, endpoint	line 290-
26	committees		adjudication committee, data management team, and	292.
27			other individuals or groups overseeing the trial, if	
28			applicable (see Item 21a for data monitoring committee)	
29				
30				
31				
32				
33	<b>Introduction</b>			
34				
35	Background and	<a href="#">#6a</a>	Description of research question and justification for	Page 5,
36	rationale		undertaking the trial, including summary of relevant	line 77-
37			studies (published and unpublished) examining benefits	100.
38			and harms for each intervention	
39				
40				
41				
42	Background and	<a href="#">#6b</a>	Explanation for choice of comparators	Page 6,
43	rationale: choice of			line 106-
44	comparators			107.
45				
46				
47	Objectives	<a href="#">#7</a>	Specific objectives or hypotheses	Page 6,
48				line 103-
49				107.
50				
51				
52				
53	Trial design	<a href="#">#8</a>	Description of trial design including type of trial (eg,	Page 5-6,
54			parallel group, crossover, factorial, single group),	line 101-
55			allocation ratio, and framework (eg, superiority,	103.
56			equivalence, non-inferiority, exploratory)	
57				
58				
59				
60				

## Methods:

### Participants, interventions, and outcomes

Study setting	<a href="#">#9</a>	Description of study settings (eg, community clinic, academic hospital) and list of countries where data will be collected. Reference to where list of study sites can be obtained	Page 6, line 112-113.
Eligibility criteria	<a href="#">#10</a>	Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and individuals who will perform the interventions (eg, surgeons, psychotherapists)	Page 7-8, line 144-157. Page 8, line 159-164; Page 10, line 210-213;
Interventions: description	<a href="#">#11a</a>	Interventions for each group with sufficient detail to allow replication, including how and when they will be administered	Page 9-10, line 188-213;
Interventions: modifications	<a href="#">#11b</a>	Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving / worsening disease)	Page 13, line 286-290;
Interventions: adherence	<a href="#">#11c</a>	Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return; laboratory tests)	Page 8, line 207-209.
Interventions: concomitant care	<a href="#">#11d</a>	Relevant concomitant care and interventions that are permitted or prohibited during the trial	n/a

1	Outcomes	<a href="#">#12</a>	Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended	Page 13, line 294-302;
12	Participant timeline	<a href="#">#13</a>	Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure)	Page 9, line183-187.
20	Sample size	<a href="#">#14</a>	Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations	Page 14, line 325-331;
28	Recruitment	<a href="#">#15</a>	Strategies for achieving adequate participant enrolment to reach target sample size	Page 14, line 330-331.
35	<b>Methods:</b>			
37	<b>Assignment of interventions (for controlled trials)</b>			
42	Allocation: sequence generation	<a href="#">#16a</a>	Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions	Page 8, line 166-175.
53	Allocation concealment mechanism	<a href="#">#16b</a>	Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered, opaque, sealed envelopes), describing any steps to conceal the sequence until interventions are assigned	Page 8, line 166-175.

Allocation: implementation	<a href="#">#16c</a>	Who will generate the allocation sequence, who will enrol participants, and who will assign participants to interventions	Page 8, line 169-175.
Blinding (masking)	<a href="#">#17a</a>	Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome assessors, data analysts), and how	Page 8, line 179-181.
Blinding (masking): emergency unblinding	<a href="#">#17b</a>	If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant's allocated intervention during the trial	Page 13, line 286-290.
<b>Methods: Data collection, management, and analysis</b>			
Data collection plan	<a href="#">#18a</a>	Plans for assessment and collection of outcome, baseline, and other trial data, including any related processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol	Page 13-14, line 309-320.
Data collection plan: retention	<a href="#">#18b</a>	Plans to promote participant retention and complete follow-up, including list of any outcome data to be collected for participants who discontinue or deviate from intervention protocols	Page 10, line 207-209.
Data management	<a href="#">#19</a>	Plans for data entry, coding, security, and storage, including any related processes to promote data quality (eg, double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol	Page 14, line 320
Statistics: outcomes	<a href="#">#20a</a>	Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the	Page 14-15, line



		statistical analysis plan can be found, if not in the protocol	332-349.
Statistics: additional analyses	<a href="#">#20b</a>	Methods for any additional analyses (eg, subgroup and adjusted analyses)	Page14, line 337-338.
Statistics: analysis population and missing data	<a href="#">#20c</a>	Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any statistical methods to handle missing data (eg, multiple imputation)	Page14, line 337-338.
<b>Methods: Monitoring</b>			
Data monitoring: formal committee	<a href="#">#21a</a>	Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed	Page13, line 290-292.
Data monitoring: interim analysis	<a href="#">#21b</a>	Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial	n/a
Harms	<a href="#">#22</a>	Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct	Page12, line 286-292.
Auditing	<a href="#">#23</a>	Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor	n/a
<b>Ethics and dissemination</b>			
Research ethics approval	<a href="#">#24</a>	Plans for seeking research ethics committee / institutional review board (REC / IRB) approval	Page 6-7, line127-129.



Protocol amendments	<a href="#">#25</a>	Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC / IRBs, trial participants, trial registries, journals, regulators)	n/a
Consent or assent	<a href="#">#26a</a>	Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32)	Page 7, line 135-137.
Consent or assent: ancillary studies	<a href="#">#26b</a>	Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable	n/a
Confidentiality	<a href="#">#27</a>	How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial	Page 13-14, line 309-320.
Declaration of interests	<a href="#">#28</a>	Financial and other competing interests for principal investigators for the overall trial and each study site	n/a
Data access	<a href="#">#29</a>	Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators	n/a
Ancillary and post trial care	<a href="#">#30</a>	Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation	n/a
Dissemination policy: trial results	<a href="#">#31a</a>	Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions	n/a
Dissemination policy: authorship	<a href="#">#31b</a>	Authorship eligibility guidelines and any intended use of professional writers	n/a
Dissemination policy: reproducible research	<a href="#">#31c</a>	Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code	n/a

## Appendices

1	Informed consent	<a href="#">#32</a>	Model consent form and other related documentation	n/a
2	materials		given to participants and authorised surrogates	
3				
4				
5	Biological specimens	<a href="#">#33</a>	Plans for collection, laboratory evaluation, and storage of	n/a
6			biological specimens for genetic or molecular analysis in	
7			the current trial and for future use in ancillary studies, if	
8			applicable	
9				
10				

11 None The SPIRIT Explanation and Elaboration paper is distributed under the terms of the Creative  
12 Commons Attribution License CC-BY-NC. This checklist can be completed online using  
13 <https://www.goodreports.org/>, a tool made by the [EQUATOR Network](#) in collaboration with  
14 [Penelope.ai](#)  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60